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ABSTRACT
Neutrophil (PMN) inflammatory functions, including cell adhesion, diapedesis, and phagocytosis, are dependent on the mobilization and release of various intracellular granules/vesicles. In
this study, I found that treating PMN with damnacanthal, a Ras family GTPase inhibitor, resulted
in a specific release of secondary granules, but not primary or tertiary granules, and caused dysregulation of PMN chemotactic transmigration and cell surface protein interactions. Analysis of
the activities of Ras members identified Ral GTPase as a key regulator during PMN activation
and degranulation. In particular, Ral was active in freshly isolated PMN, while chemoattractant
stimulation induced a quick deactivation of Ral that correlated with PMN degranulation. Overexpression of a constitutively active Ral (Ral23V) in PMN inhibited chemoattractant-induced
secondary granule release. By subcellular fractionation, I found that Ral, which was associated

with the plasma membrane under the resting condition, was redistributed to secondary granules
after chemoattractant stimulation. Blockage of cell endocytosis appeared to inhibit Ral translocation intracellularly. In conclusion, these results demonstrate that Ral is a critical regulator in
PMN that specifically controls secondary granule release during PMN response to chemoattractant stimulation.
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CHAPTER I
GENERAL INTRODUCTION
1. Neutrophils (PMN)
Neutrophils, also termed PMN, are polymorphonuclear leukocytes characterized by their multilobed nuclei [1]. PMN, which are generated from bone marrow, are abundant cells in circulation
and account for 40-75% of all leukocytes [2]. Up to 1-2×1011 PMN are steadily generated per
day in a healthy adult [3]. Constant numbers of PMN in the circulation are very crucial for maintaining host homeostasis [4-6]. Granulocyte colony stimulating factor (G-CSF) has been shown
to positively regulate PMN production in bone marrow, but G-CSF is not completely required
for PMN generation [7-8]. The release of PMN from bone marrow is largely dependent on
CXCR4 [9]. It is likely that CXCR4 functions a gatekeeper for blocking PMN migrating out of
bone marrow [10-15]. In CXCR4-deficient chimera mice, myeloid precursors are significantly
decreased and peripheral granulocytic cells are increased by about three-fold compared with wild
type-litter mates [16-17]. Blocking CXCR4 function with the inhibitory antibody/antagonist,
AMD3100, elevates PMN counts in circulation [10, 14-15]. Additionally, AMD3100 dosedependently increases the release of CD34+ hematopoietic progenitor cells into circulation as
demonstrated in healthy human volunteers [10, 14]. Presumably, the negative effect of CXCR4 is
through the signaling cascade of CXCL12 (stromal derived factor-1, SDF-1)/ CXCR4 [18]. Under the influence of inflammation, however, PMN production is increased. In circulation, nonactivated PMN have 8-16 hours average half-lives [19]. After stimulation, active PMN are recruited to the target tissue where they survive for only 1-4 days [20-21]. PMN are disposed from
circulation mainly at the spleen, liver, bone marrow and the site of inflammation [22-24]. Macrophages play a pivotal role in the clearance of both circulating PMN under nonpathologic con-
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ditions and inflammatory PMN in the target tissue [4]. In addition to macrophage phagocytosis,
PMN apoptosis [21] is also a key factor in preventing excessive PMN infiltration-mediated inflammation, tissue damage and organ dysfunction, thus maintaining cellular homeostasis.

PMN are the first cells recruited to the site of an infection [25]. Recruitment of circulating PMN
from blood vessels to the site of inflammation is very important for eliminating invading microorganisms, recovering tissue damage and maintaining homeostasis [26]. Through releasing reactive oxygen species, antimicrobial proteins, proteolytic enzymes and producing cytokines, as
well as performing phagocytosis, PMN eliminate microorganisms, and thus are essential for innate immunity [27]. Most notably, PMN infiltration is the hallmark of the early stages of the inflammatory response [28]. On the contrary, dysregulated PMN functions are also closely linked
to tissue damage and organ dysfunction.

I.

Chemoattractants and their receptors in PMN transmigration

Leukocyte chemoattractants include interleukin (IL)-4, IL-8, platelet-activating factor (PAF), and
formyl-Methionyl-Leucyl-Phenylalanine (f-Met-Leu-Phe, fMLF), leukotriene B4 (LTB4), C3a
and C5a [29]. Leukocyte chemoattractants can be further grouped into several main categories
such as chemokines [30], bacterial products, immunoproducts, phospholipids, etc. They are released by numerous types of cells. For example, activated endothelial cells secrete IL-4, LTB4,
and PAF, while activated stromal cells, including macrophages, epithelial cells, etc. secrete
LTB4 and PAF. In addition, bacteria or dying cells release fMLF [31]. The combination of
chemoattractants and their gradient drives PMN chemotactic migration towards an inflammatory
site [31] (Figure 1-1).
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According to derivation, chemoattractants can be further divided into “regulatory cell-derived
chemoattractants” and “end target-derived chemoattractants”. Regulatory cell-derived chemoattractants include IL-8 and LTB4, etc. End target-derived chemoattractants are mainly composed
of fMLF, derived from bacteria or the mitochondria of dying cells, and complement C3a and C5a
[31]. Migrating out of the blood stream, PMN encounter a combination of chemoattractants released from the endothelium and infected tissues. Through integration of those series of chemoattractants, PMN effectively reach the target site. It has been proposed that chemoattractant
receptor cross-desensitization is one of the mechanisms regulating PMN chemotaxis [32-34].
Moreover, the combinational and sequential signals of distinct chemoattractants navigate PMN
chemotaxis to a great extent [35-37]. When placed in a chemoattractant gradient, PMN vigorously migrate towards the gradient in spite of the original migration pathways. Furthermore, PMN
are able to integrate signals from different chemoattractants, and thus migrate toward the target.
End target-derived chemoattractants, such as fMLF and C5a, however, are substantially dominant over cell-derived chemoattractants, such as IL-8 and LTB4 [35-37].

Pre-exposure with fMLF or C5a causes PMN to lose the response to IL-4 and LTB4. This phenomenon might be a reasonable explanation for the fact that PMN respond to eliminate existing
invading bacteria first compared to tissue damage. It has also been demonstrated that PMN fail to
transmigrate towards IL-4 or IL-8 when cells are pre-treated with fMLF or C5a in the presence
or absence of an endothelial monolayer. This desensitization of PMN is likely associated with
the polymerization of actin filaments [36], because the end target-derived chemoattractants trigger sustained and prolonged actin polymerization. Other studies have shown that PMN are able
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to migrate down a concentration gradient towards another chemoattractant. They can also migrate beyond the inhibitory maximum concentration toward another different chemoattractant
[35]. In addition to the signals received by PMN upon stimulation with different chemoattractants, chemoattractant receptor cross-desensitization also plays a key role in PMN chemotaxis.
Cpd43, an agonist of formyl peptide receptors 1 and 2, not only inhibits the ability of PMN to
further respond to IL-8, C5a and LTB4, but also results in the loss of the expression of CXCR1,
CXCR2, C5a and LTB4 on cell surface [33]. Treatment of PMN with fMLF or C5a reduces the
binding of IL-8Rβ to its antibody [34]. These miscellaneous factors enable PMN efficiently and
precisely mobilize to their targets through a complex chemotactic field.
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Chemoattractants
Bacterial products: fMLF

Activation

Migration

Degranulation

Chemokines: IL-8, IL-4
Immunoproducts: C3a & C5a
Phospholipids: LTB4

Bind to cell surface GPCR

Figure 1-1. PMN activation and category of chemoattractants
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II.

Chemoattractant, fMLF-mediated signaling transduction cascade in PMN

Various signaling pathways are implicated in PMN migration. One of the well characterized
pathways is fMLF-mediated PMN stimulation [38] (Figure 1-2). Upon fMLF binding, its trimetric G-protein-coupled receptor (GPCR), composed of α, β, and γ subunits [39], is activated and
undergoes a conformational change. Ligand binding induces the switch of GDP-bound inactive
form to the GTP-bound active form, resulting in the low affinity of Gα towards Gβγ. The dissociation of Gα with Gβγ activates its own individual downstream effectors, including phosphatidylinositol-specific phospholipase-Cβ (PLCβ), adenylyl cyclase and phosphatidylinositiol-3 kinase isoforms (PI3K).

Activated PLCβ hydrolyzes PI 4, 5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 then diffuses into the cytosol, binds to the IP3 receptor and results in
Ca2+ release from ER storage. Released Ca2+ involves in activation of PKC and triggers extracellular calcium influx, presumably through the interaction of the IP3 receptor with plasma membrane channels [40-42]. Ca2+, a pivotal second messenger, is crucial for the reorganization of actin filaments. Ca2+ facilitates the binding of myosin, the motor protein, to actin through exposing
the myosin binding site on actin, and thus is involved in plasma membrane protrusion, lamellapodia formation, and PMN migration [43]. DAG activates protein kinase C (PKC), thus resulting
in a series of protein phosphorylation. Serving as a second messenger, PKC further activates a
series of downstream signaling molecules involved in PMN adhesion [44-45]. In PMN, PKC also associates with the respiratory burst [46]. There are five isoforms of PKC expressed in PMN,
including PKC-α, PKC-β1, PKC-βII, PKC-δ, and PKC-δ [47]. It has been shown that, shortly
after fMLF stimulation, PKC-α, PKC-β1, PKC-βII and PKC-δ activate NADPH oxidase, leading
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to superoxide anion generation [47]. As demonstrated by in vitro phosphorylation assays, among
the different PKC isoforms are PKC-α, PKC-βII, PKC-and PKC-δ phosphorylate p47phox and
DADPH oxidase [48]. Inhibition of PKC-β with its specific inhibitor results in abolished activity
of NADPH oxidase activity induced by PMA [49]. PKC-β-/- mice, however, show a defect only
in NADPH oxidase activity, suggesting that PKC-β may not be associated with PMN migration
[49-50].

Upon dissociation with Gα, the Gβγ subunit also activates PI3K, leading to actin polymerization
[51-53]. PMN express four types of PI3K, including PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ [54],
which are involved in cytoskeleton organization and respiratory burst. PI3Kγ-/- PMN demonstrate impaired migration in Casein- and Listeria–induced peritonitis mice models [55], and abolished transmigration towards fMLF as illustrated in in vitro transmigration assays [50, 55]. Inhibition of PI3Kδ by a specific inhibitor, IC8711, diminishes PMN spreading in response to
fMLF stimulation, and also blocks PMN chemotaxis [56], implicating the important role of
PI3Kδ in PMN directional movement. Similar effects are also observed in wortmannin or
LY294002 (PI3K inhibitors) -treated HL-60 cells [57]. Treatment of PMN with wortmannin, reverses anti-β3-integrin mAb-mediated inhibited migration in response to fMLF [54], suggesting
that the effect of PI3K in PMN migration is likely through targeting β3-integrin. PI3γ, on the
other hand, also contributes to PMN respiratory burst through phosphorylating PIP2 into PI 3, 4,
5-bisphosphate (PIP3), which activates PKC [53].

In contrast to PLCβ and PI3K, the role of adenylyl cyclase in PMN is not well understood. Studies have shown that fMLF leads to a transient increase of cAMP in PMN through augmenting
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the adenylyl cyclase response [58]. Elevated cAMP has been shown to inhibit PMN chemotaxis
to fMLF [59]. However, limited studies exploring the role of cAMP in PMN utilizing inhibitors
of phosphodiesterase have been performed. Blocking the breakdown pathway of cAMP using
inhibitors of phosphodiesterase results in markedly impaired adhesion of PMN to the endothelium and decreased cell surface expression of CD11b/CD18 [60], suggesting adenylyl cyclase is
involving in the PMN adhesion step.

Moreover, fMLF activates Rho small GTPase, including Rho, Rac and Cdc42, all of which regulate PMN migration through affecting actin filament formation [39, 52]. The MAPK cascade is
also activated after fMLF stimulation, thus leading to chemotaxis activation and superoxide production [38-39]. Considering the complex signaling cascades in stimulated PMN, the fMLFmediated signaling pathway is very critical to PMN chemotactic migration and superoxide production.
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Figure 1-2. fMLF-mediated activation pathway in PMN.
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III.

Key adhesion molecules involved in PMN transendothelial and transepithelial migration

As a first line of defense, PMN are required to respond quickly to the invading microorganism.
They transmigrate toward the sites of injury or inflammation under the influence of the chemoattractant gradient. Depending on the target site, PMN transmigration toward the infectious site is
generally composed of transendothelial migration and transepithelial migration (Figure 1-3).
Along the process, PMN transform from resting cells into activated cells and directionally migrate toward the target site. A variety of adhesive molecules, cell surface receptors, signaling
molecules and adaptor molecules are involved in this transition.

Upon chemoattractant stimulation, adhesion molecules are gradually released from secondary
and tertiary granules of PMN to the surface. This vital degranulation process enables PMN to
adhere and migrate across the vascular endothelium and tissue layers [26, 61-65]. β2 integrin
CD11b/CD18, also termed as Mac-1 or αMβ2 [66-67], and Ig superfamily members, including
CD47 and SIRPα [68-71], are all required for PMN adhesion and chemotaxis. PMN transendothelial migration (Figure 1-4) is composed of tethering and rolling, adhesion and transmigration
[26, 31, 65, 72]. Among those steps, integrin CD11b/CD18 (Figure 1-5) plays a conclusive role
in the PMN adhesion step through interacting with its ligand, intercellular adhesion molecule
(ICAM)-I [73] located on endothelial cells. It has been shown that CD11b/CD18, mainly localized in the secondary granules of PMN, translocate into the plasma membrane upon stimulation
of PMN with fMLF, PMA or ionomycin [74]. The attachment of activated PMN to unstimulated
human umbilical vein endothelial cells (HUVEC) is blocked in the presence of anti-CD11b monoclonal antibodies (mAbs) [75-77]. The adherence of unstimulated PMN to stimulated HUVEC
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is also inhibited by anti-CD11bAb, LM2/1 [78]. In CD11b/CD18 deficient mice, the attachment
of PMN to ICAM-1 is decreased compared with wild-type mice [79].

CD11b/CD18-mediated adhesion not only extensively contributes to transendothelial migration
but also transepithelial migration (Figure 1-6). PMN transepithelial migration consists of adhesion, migration and post-migration [67, 80-81]. Adhesion of PMN to epithelial cells is mediated
by the interaction of CD11b/CD18 on PMN with its ligands, fucosylated proteoglycan(s), located
on epithelial cells. This interaction triggers the opening of apical junction complex mainly
through regulation of myosin phosphorylation. As a result, following phosphorylation, junction
complexes open and facilitate PMN transmigration. Upon reaching the lumen, CD11b/CD18 interacts with ICAM-1 on the apical epithelial site and further assists PMN transepithelial migration toward the damaged site [65].

In addition to CD11b/CD18, CD47, SIRPα and JAM-A are also actively involved the process of
PMN transmigration. CD47 (Figure 1-7) is an important regulator in facilitating PMN transmigration. In PMN, CD47 is kept in the secondary granules and is re-distributed to the cell surface
after chemoattractant stimulation, leading to the promotion of PMN migration [69]. It was first
discovered that PMN migration was inhibited in the presence of anti-CD47 antibodies [71, 8283]. Later research further demonstrated PMN transmigration across T84 monolayers and cellfree collagen-coated filters is delayed when cell are treated with inhibitory anti-CD47 antibodies
C5D5 and B6H12 [69]. Indeed, functionally inhibitory anti-CD47 mAbs delay, but do not block,
the process of PMN transepithelial migration and migration across a collagen-coated transwell
toward fMLF [69]. When challenged with Escherichia coli, CD47-/- mice demonstrated a defect
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in the early stages of PMN migration [84]. In addition to its effect in PMN, CD47 has been implicated in the migration in other cell types. Likewise, CD47-/-epidermal dendritic cells (DCs)
demonstrate decreased migration toward draining lymph nodes in vivo [29]. Transduction of
neuroblastoma cells with CD47 results in neurite and filopodium formation [85]. Additionally,
through in vitro experimentation, it is uncovered that CD47 is important for the migratory activity of B cells [86].

SIRPα (Figure 1-7), a counter ligand for CD47 [87], also contributes greatly in PMN migration.
Similar to the distribution of CD47 in PMN, SIRPα translocates from secondary granules to the
cell surface after fMLF stimulation [68, 70]. PMN transepithelial migration is inhibited using
anti-SIRPα mAbs. The SIRPα-CD47 interaction leads to significantly decreased PMN migration
[68], suggesting that SIRPα delivers a negative signal to PMN migration through its immunoreceptor tyrosine-based inhibition motif (ITIM).

Junctional adhesion molecule-A (JAM-A) is also engaged in regulating PMN migration, particularly in PMN transendothelial migration [81, 88]. JAM-A redistributes to the cell surface under
inflammatory condition [89], thus facilitating PMN migration. Treatment of HUVECs with a
blocking antibody against JAM-A [90] impairs PMN transmigration. The effect of JAM-A is
likely through the interaction of JAM-A with its ligand, β2 integrin LFA-1, on leukocytes [90].
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Figure 1-3. PMN transmigration to the target site. Depending on the target site, PMN transmigration towards the infectious site is generally composed of transendothelial migration and transepithelial migration.
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Figure 1-4. PMN transendothelial migration.
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Figure 1-5. Putative structure of integrin CD11b/CD18. CD11b/CD18 is composed of α and β
subunits.
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2. Inflammation
Throughout evolutionary history, human beings have continued to defend against invasion by
microorganisms. We successfully resist to infections most of time because of our complex immune system. The immune system includes both the innate immunity and the adaptive immunity.
Innate immune immunity takes place first and occurs within the first 96 hours. PMN and macrophages are the key players for innate immunity. Through phagocytosis, they eliminate invading
microorganisms. Incomplete clearance results in the response of the adaptive immune system
mainly involving in lymphocytes. Coordination of the innate immunity with the adaptive immunity is crucial to fight efficiently against infection.

Inflammation is an innate immune response to local injury or infection [28] (Figure 1-8). The
occurrence of inflammation is due to insufficient removal of invading microorganism. In inflammation, innate immune response takes place first [91]. In the local environment, resident tissue cells sense the presence of pathogens, secret cytokines acting on other cells and trigger the
innate immune response. Under the influence of cytokine networks, vascular dilation occurs and
edema takes place, characterized by the leaking of plasma and fluid into connective tissues due
to the permeability change of endothelial cells. At the same time, edema leads to a change in the
nervous system, thus resulting in a feeling of pain [28]. In addition to vascular events, cellular
events also play a primary role in inflammation. In the local environment, high concentrations of
chemoattractants secreted by activated stromal cells, including activated endothelia cells and macrophages, etc. [31], and increased surface expression of adhesion molecules on the endothelium
lead PMN to undergo rolling, activation, adhesion and transmigration across the endothelial mo-
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nolayer to the targeted tissue to release anti-microbial substances and phagocytize pathogens
[92].

PMN are vital for the beginning stage of inflammation [25]. PMN infiltration is the hallmark of
the early-stage of inflammatory response [28]. After they arrive at the target site, PMN execute
their function by releasing reactive oxygen species, antimicrobial proteins and proteolytic enzymes, as well as by producing cytokines and performing phagocytosis [27]. Thus, sufficient recruitment of PMN is very important for eliminating invading microorganisms, recovering tissue
damage and maintaining homeostasis [26]. In particular, during acute infection and inflammation, PMN sense chemoattractant signals and swiftly migrate across the microvasculature and
underlying tissues to accumulate at inflammatory foci. Here, these cells execute forceful antimicrobial and tissue damaging functions. Therefore, the timely and precise response of PMN is critical for innate immune response.

In spite of the critical role of PMN in acute inflammation, efficient removal of PMN in the late
stage of inflammation is substantial [93-94]. PMN apoptosis [95] and removal by macrophages
control the extent of inflammation. The prolonged existence of PMN in the targeted tissue also
frequently results in host-tissue damage. PMN-mediated inflammation is one of the central components of many pathophysiological processes; thus, diseases in which dysregulated PMN
transmigration and activation occur often result in severe tissue injuries and organ dysfunction
[25, 96]. Many active stage of human diseases are characterized by excessive PMN infiltration,
including bacterial infection, inflammatory bowel disease, ischemia-reperfusion injury, rheumatoid arthritis, etc. [31].
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Furthermore, resident tissue cells such as macrophages and dendritic cells contribute largely to
inflammation [93-94, 97-98]. After engulfing pathogens, macrophages secrete cytokines to further recruit other cells for assistance. After engulfing pathogens, dendritic cells migrate toward
secondary lymphoid organs to induce adaptive immune responses. Upon dendritic cell migration
into the secondary lymphoid organs, degraded pathogens are presented by major histocompatibility complex (MHC) on the surface and recognized by naive T lymphocytes. Activation through
recognition of the MHC-antigen complex with T cell receptors and co-stimulatory signals causes
pathogen-specific T lymphocytes to differentiate to T helper cells or cytotoxic T cells. T helper
cells are able to activate B cells leading to the generation of plasma cells and secrete antibodies.
Some plasma cells and antibodies leave lymphoid organs and enter infectious tissues for eliminating pathogens. Through releasing cytokines, T helper cells also further activate macrophages
in the tissue to increase their abilities to phagocytize pathogens. Compared with T helper cells,
cytotoxic T cells migrate to the target tissue and directly remove pathogens through releasing
cytotoxins or inducing apoptosis through a Fas ligand-Fas interaction. In conclusion, inflammation is a complex process whereby innate immunity coordinates with adaptive immunity to fight
against pathogens.
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Figure 1-8. PMN play a pivotal role in inflammation. PMN infiltration is the hallmark of the early stage of the inflammatory response.
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3. PMN granules
Different from other cells types, circulating PMN only express a few cell surface proteins [62].
Instead, they keep most of those proteins in special membrane bound storages called granules
[61] (Figure 1-9). According to size and morphology, PMN granules are composed of four categories, primary granules (azurophil granules), secondary granules (specific granules), tertiary
granules (gelatinase granules) and secretory vesicles [63]. Each granule contains different protein
components and possesses distinct functions.

Primary granules, regarded as lysosomes, undergo limited degranulation in response to outside
stimuli [99]. Primary granules are important storage for antimicrobial proteins, serine proteases
[100-101] including elastase and cathepsin G [102], and proteinase 3 [63]. Myeloperoxidase
(MPO) is a marker for primary granules [103]. It plays a key role in PMN phagocytic function,
due to its strong antimicrobial activity [104], through interaction with H2O2 formed by superoxide anions in the respiratory burst system. During the process of phagocytosis, serine proteases,
localized inside phagolysosome, work together with hypochloric acid, a final product generated
in a series of reactions catalyzed by MPO, to execute antimicrobial activities. In addition to killing microorganisms in phagolysosomes, elastase are also released during PMN activation in response to various chemoattractants stimulation [105]. Upon release, serine proteases play a very
important role in chemokine modification that leads to an increased binding affinity towards the
chemokine receptor. Chemokines modified by serine proteases gain increased chemotactic activity for PMN ,and thus, are essential for PMN migration [100]. Serine proteases are also capable of cleaving intercellular adhesion molecules, ICAM-1 [106], vascular cell-adhesion molecule
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1 (VCAM-1) [107] and epithelial (E)-cadherin [108], thus facilitating PMN transmigration
across the endothelium and epithelial cells. As a result, certain primary granules not only function as lysosomes during PMN phagocytosis, but also contribute to the interaction between PMN
and the extracellular matrix during PMN migration.

Secondary granules are important stores of adhesion molecules, membrane receptors and other
critical proteins, such as lactoferrin, fMLF receptors, CD47, SIRPα, and CD11b/CD18, facilitating PMN migration [63, 68-69]. Lactoferrin is a marker of secondary granules [103], and its antimicrobial activity comes from competing with microorganisms for iron [109]. PMN from patients with neutrophil-specific granule deficiency [110] are defect in chemotaxis in response to
stimuli, decreased binding capability to fMLF, decreased antibacterial activity and less activity in
response to fMLF stimulation. Other cases of PMN secondary granule deficiency also illustrated
decreased chemotaxis and impaired killing of microorganisms [111]. These characteristics further suggest that secondary granules, enriched in receptors and adhesion molecules, are indispensable for PMN to execute anti-infection functions.

Tertiary granules serve as reservoirs of matrix-degrading enzymes [63]. The key component in
tertiary granules is gelatinase. Gelatinase, also termed matrix metalloproteinases (MMPs), enzymatically digest extracellular matrix proteins during PMN transmigration. In human PMN, two
MMPs have been identified. They are MMP-9 (92KDa) and leukolysin (MT6-MMP/MMP-25)
(56KDa) [63, 112]. Compared with secondary granules, tertiary granules are more mobilized and
easily exocytosed upon stimuli activation [99].

A.

PMN Granules
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A. Primary granules (azurophil granules)
B. Secondary granules (specific granules): lactoferrin, CD47, integrin, SIRPα

C. Tertiary granules (gelatinase granules)
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Figure 1-9. PMN granules types (A) and degranulation (B) in response to stimulation (e.g.
fMLF).
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Secretory vesicles are highly mobilized [99], and they contain membrane-associated receptors
and are able to furnish PMN with the first batch of proteins for sensing and triggering activation
during PMN-mediated immune responses [61]. Secretory vesicles contain the marker protein albumin [113]. It has been demonstrated that albumin is originally from PMN plasma membranes,
not from new synthesis, suggesting that albumin comes from endocytosis pathway. The quick
interchange of albumin between the plasma membrane and secretory vesicles further implies that
secretory vesicles are very sensitive to exocytosis. Furthermore, PMN are able to mobilize secretory vesicles even in the absence of stimulation [114].

The classification of granules does not only rely on the size and morphology of granules. The
components in each granule depends on the time that those proteins are synthesized (targetingby-timing hypothesis) and the characteristics of each protein, i.e. whether it is able to co-exist to
avoid degradation [99]. In addition to the presence or absence of MPO, the major difference between the secondary and primary granules lies in the fact that proteases stored in primary granules are in activated forms; proteases in secondary granules exist as latent forms and need to be
activated after release from PMN. However, the detailed mechanisms underlying processing and
targeting of granule proteins in PMN are unclear. It has been implied that the Golgi network is
likely to function as a sorting apparatus in PMN [61]. Studies of serine proteases stored in primary granules have shown that glycosylation, a major function of the Golgi network, is not required
for granule protein targeting [99]. Specifically, Cathepsin G does not require glycosylation for
granule targeting [115]. Through site-directed mutagenesis, Cathepsin G lacking an N-linked
glycosylation site was still shown to be transported to lysosomes. In addition to protein confor-
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mation and modification, such as glycosylation, protein-protein interaction is also crucial for correct granule targeting, particularly for lactoferrin, which is a key component for secondary granules [103]. A study on transport of newly synthesized lactoferrin demonstrated that the transport
of lactoferrin was blocked by interfering ionic interaction at the plasma membrane and acidification environment inside the cell [103].

To date, the most sufficient experimental approach to investigate the localization of proteins of
interest in PMN is subcellular fractionation, which has been previously demonstrated to successfully separate neutrophil plasma membranes from intracellular granules [70, 116]. Thus, in this
study, a series of these experiments were performed to identify the localization of Ral in PMN.

4. Mechanisms underlying granule release
Mobilization of intracellular granules and vesicles also contributes, to an extraordinary degree, to
PMN migration. As we know, cytoplasmic granules and vesicles of PMN are composed of not
only antimicrobial proteins and proteolytic enzymes for eliminating foreign microorganisms but
also a variety of cell surface receptors, functional proteins and granule matrix proteins involved
in PMN extravasation. During degranulation, the PMN cell surface is incorporated with granule
proteins and receptors. Subsequently, those fused proteins facilitate the activation of resting
PMN to engage in cell-cell interactions and cell-extracellular matrix interactions in the process
of transmigration. CD47, as an example, has been illustrated to facilitate PMN migration only
after re-distribution from secondary granules to the cell surface upon chemoattractant stimulation
[69]. As a result, controlled and effective degranulation of PMN is very important in inflammation and preventing overwhelming PMN-mediated tissue damage, thus maintaining homeostasis.
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However, the molecular mechanism(s) by which PMN regulate individual intracellular granule
release is still unclear. The signaling events elicited by chemoattractant stimulation (e.g. fMLF)
leading to the release of each type of granule are still unclear. In other cell types, Ral, a Ras
family small GTPase, involves in intracellular vesicle transportation, including both endocytosis
and exocytosis [117-121]. Small GTPases are monomeric G proteins that are actively involved in
many cellular functions [122]. They are further divided into five families based on sequence:
Ras, Rho, Rab, Ran and Sar1/Arf [123]. According to structure, there are two interconvertible
forms of small GTPases: GTP-bound active form and GDP-bound inactive form (Figure 1-10).
Upon upstream activator binding, GDP is dissociated from the small GDP-bound form because
of the conformation change, and is replaced with GTP. The GTP-bound form relays the signal
from upstream to downstream through binding downstream effectors [122]. As a result, small
GTPases serve as a molecular switch in signaling cascades. The interexchange of the GTP-bound
form with the GDP-bound form is controlled by guanine nucleotide exchange factor (GEF) and
GTPase activating protein (GAP). GEF triggers the formation of GTP-bound active form. GAP,
increases the conversion of GTP to GDP, thus resulting in the formation of GDP-bound inactive
form [122].
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Figure 1-10. Interchange of the GTP-bound form with the GDP-bound form of small GTPase.
GEF: guanine nucleotide exchange factor; GAP: GTPase activating protein.
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Given the importance of Ral in other cell types, in this study, the potential role of Ral in regulating PMN granule mobilization and chemotactic function was investigated.

To date, the dynamics of actin cytoskeleton, Ca2+ signaling, src family kinases, β-arrestin, small
GTPases and SNARE molecules have been reported to be involved in PMN degranulation.

Small GTPases play important roles in regulating PMN granule release. Rac2, a Rho family
GTPases family member, is pivotal for neutrophil primary granule release [124-127]. Rac2-/mice have shown defects in PMN primary granule release but not secondary or tertiary granule
release. Rac2-/- mice also demonstrated defects in the translocation of primary granules [124].
Bone marrow PMN isolated from Rac2-/- mice fail to release primary and tertiary granules upon
fMLP, LTB4, and CB-LTB4 [125] stimulation. In addition, Rac2 is also associated with superoxide anion (O2–·) production [125]. In animal models and patients, the Rac mutation D57N,
characterized by the loss of binding capability to GTP, has been [110, 127] found to prevent the
MPO release and superoxide anions production in response to fMLF and phorbol myristate acetate (PMA), but not the release of secondary granules [126].

Rab, a family protein of small GTP, have been widely studied in targeting vesicles to particular
compartments through tethering. In PMN, Rab27a has been implicated in regulating primary
granule release through interacting with its effector protein JFC1/Slp1 [128-129]. Rab27-/- mice
fail to release MPO upon LPS challenge. Subcellular distribution of Rab27a by fractionation and
immunofluorescence staining further supports the fact that Rab27 is a constituent of exocytotic
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machinery of primary granules in PMN. Rab27b has also been demonstrated to be the key component in regulating PMN primary granule release [130].

Rap1 and Rap2 are associated with PMN secondary granules but not primary granules or cytosol,
as demonstrated by PMN subcellular fractionation and immunostaining. Accompanied with degranulation, Raps translocate to the plasma membrane from secondary granules, further suggesting their roles in controlling PMN secondary granule release [131].

Studies have also found that Rho family small GTPases regulate granule release. Pretreatment of
PMN with MAPK phosphorylation inhibitors diminishes phagocytosis of C albicans and granule
mobilization. Similarly, overexpression of the dominant-negative Rac and Cdc42 in PMN,
through viral delivery, leads to abolished phagocytosis and granule release, implicating Rac and
Cdc42 in regulating PMN granule release through the MAPK signaling pathway [132].

As a key component of the cytoskeleton, actin filaments not only contribute to cell motility, but
also intracellular trafficking [133]. They are also involved in endocytosis and exocytosis [134].
Dynamic actin assembly and disassembly are associated with PMN primary granule release. In
particular, actin polymerization is likely to initiate the release of primary granules. Primary granules are released from PMN treated with fMLF and cytochalasin B (CB) [135]. However, stabilization of actin results in inhibition of primary granule release. Inhibition of Rac also leads to
reduced primary granule release through jeopardizing F-actin formation. Another study has suggested that the actin cytoskeleton might regulate the release of all types of granules in the PMN
in response to stimulation [136]. With the exception of secretory vesicles, CB significantly in-

31

creases fMLF-simulated secondary and tertiary granule release. Additionally, CB triggers primary granule release that is failed to be released by fMLF alone. All of the above suggest that the
actin cytoskeleton restricts the release of granules and maintains PMN in the resting condition. In
addition to actin filaments, microtubules have been demonstrated to be associated with PMN
granules [137]. Granule-microtubules, including primary granule-microtubule complexes and
secondary granule-microtubule complexes, have been isolated from PMN, suggesting the critical
role of microtubules in regulating PMN granule release.

During granule release, tethering and fusion of vesicles toward the target compartment involves a
complex process that is not well understood. SNAREs, (soluble NSF (N-ethylmaleimidesensitive factor), are key proteins involving in the docking and fusing of vesicles to the target
compartment [138-140]. In human PMN, (t-) SNARE isoform syntaxin 6 has been cloned and
shown to be localized only in the plasma membranes of resting and activated PMN [141]. In contrast to syntaxin 6, SNAP-23, another isoform of (t-) SNARE, localizes in tertiary and secondary
granules in PMN and translocates to the plasma membrane upon stimulation. Antibodies against
SNAP-23 block secondary granule release, whereas, anti-syntaxin 6 antibodies, block primary
and secondary granule release from PMN. The above suggest that SNAP-23 and syntaxin 6 particularly regulate secondary and primary granule release. Vesicle-associated membrane protein
(VAMP)-7, a (v-) SNARE in PMN [142], has been detected in primary granules in PMN. Treatment of PMN with antibodies against VAMP-7 dose-dependently abrogates primary granule,
secondary granule and tertiary granule release. VAMP-2 and syntaxin 4 are associated with secretion of secondary and tertiary granules from PMN [143]. VAMP-2 is identified in PMN. Application of specific antibodies against 2-17aa in the N terminal of VAMP-2 to electropermeabi-
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lized PMN leads to the inhibition of secondary and tertiary granule release, but not primary granule release from PMN. This suggests an important role for VAMP-2 in release of those two
granules PMN. Furthermore, VAMP-2 has also been suggested to control granule release in
PMN after stimulation through interaction with syntaxin 4, which was demonstrated by the coimmunoprecipitation assay. Regarding the different types of granules in PMN, distinct SNAREs
are likely to associate with each individual granule, and thus regulate PMN granule release.

Although signaling pathways regulating PMN granule release are not well understood, GPCRmediated signaling cascades in PMN activation have been well established. As a scaffold protein, β-arrestin has been shown to be involved in PMN granule release. Upon IL-8 binding to
CXCR1 on PMN [144], β-arrestin binds to phosphorylated receptors and forms more β-arrestinHck complexes. It has been demonstrated that β-arrestin translocates from the plasma membrane
to secondary granules in PMN upon stimulation, suggesting its potential role in regulating PMN
secondary granule release.

The effect of Src family kinases has also been demonstrated. P59Hck was first found to be mainly
localized on granules, in contrast to plasma membranes and cytosol, in PMN [145]. Subsequently, it is found to be localized only on primary granules in PMN and is translocated to phagosomal
membranes in HL60 cells during phagocytosis, indicating its role in regulating fusion of primary
granules with lysosome. P55c-fgr has also been detected in human PMN and it is present in PMN
membrane portions mainly on the plasma membrane of secondary and tertiary granules. P55 c-fgr
partially translocates to the plasma membrane in PMN stimulated with fMLF together with
CB[146], suggesting its role in granule release. hck-/-fgr-/- PMN demonstrate the diminished re-
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lease of lactoferrin in response to TNF stimulation when cells are placed in tissue culture plates
or on collagen coated surfaces, suggesting that hck and fgr are involved in PMN adhesiondependent granule release [147].

Calcium signaling also plays an essential role in PMN degranulation. It has been shown that increased intracellular calcium levels leads to release each type of granules in a hierarchical order
[148]. Raised intracellular calcium is not only led by extracellular calcium influx, but also by
other factors. It has been demonstrated that intracellular calcium in PMN is increased by ligation
of L-selectin with its ligand, sulfatides [149], fMLF stimulation [149] and cross-linking of
CD11b/CD18 on the PMN surface using its mAb [150]. Particularly, ligation of CD11b/CD18
induces the activation of cytoplasmic protein tyrosine kinases, such as p58fgr, resulting in
CD11b/ CD18 dependent tyrosine phosphorylation. Patients with loss of β2 integrins fail to response to TNF-mediated tyrosine phosphorylation in PMN [151-152]. Furthermore, activation of
CD11b/CD18 phosphorylates and activates a series of proteins. The effect of CD11b/CD18
might be Ca2+ dependent [153-154].

In PMN, several annexins have been identified [155]. Among them, annexin I is associated with
secondary granules, the plasma membrane and secretory vesicles, but not primary granules. The
effect of Annexin I likely depends on high concentrations of Ca2+ [156]. Annexin II, IV and VI
are associated with all of the granule populations. The above suggests that different isoforms of
annexin convey distinct effects on the release of different categories of granules from PMN.

5. Ral
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The molecular mechanisms underlying PMN degranulation are still poorly understood. Considering the complex signal cascades involved in each type of granule release, it still remains unclear
how PMN control the orderly release of individual granule subsets in response to different stimuli.

Ral is a member of Ras small GTPases. Like other small GTPases, Ral activity is regulated by
GAP and GEF. To date, six GEFs have been identified. Based on structural similarity, they are
further divided into two subfamilies. The first family of Ral GEFs is composed of RalGDS,
ralGDS-like (Rgl), RalGDS-like factor (Rlf), and Ral GEF-like 3 (Rgl3). They contain Ras-GTPbinding domains, suggesting that Ral is activated through a Ras-dependent pathway. The other
family consists of RalGPS2/RalGEF2 and RalGPS2, without a Ras-GTP-binding domain, suggesting the Ras-independent pathway for Ral activation [157]. Compared to GEFs, only two
GAPs, GAP1 and GAP2 [157], have been identified by in vitro experiments. Ral activation involves complex signal cascades including both Ras-dependent [158-161] and Ras-independent
pathways [162-163]. Studies by Rob M.F. Wolthuis demonstrate that Ral activation requires Ras
activation [158]. Most importantly, Ral activation correlates with Ras activation. In contrast, other studies have also illustrated that the Ras-independent activation mechanism also extensively
contributed to Ral activation [162-163]. In Rat-2 cells [162], not only does Ral activation require
Ras activation, but is also triggered by increasing intracellular Ca2+ using ionomycin. Meanwhile, PLC is also required for Ral activation induced by LPA or EGF. Ca2+ -mediated Ral activation is observed in platelets as well. Increased intracellular calcium levels and/or increased
calcium influx lead to Ral activation in platelets [163]. Bhattacharya M et al., using human embryonic kidney 293 cells (HEK293), discovers that RalGDS dissociation from beta-arrestin and
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translocation to the plasma membrane leads to Ral activation [164]. This result implies an essential function for Ral in cytoskeletal reorganization and granule release.

The detailed mechanism that inactivates Ral, however, is still unknown. Thus, it is critical that
more studies exploring this mechanism be performed. In particular, Ral deactivation is critical
for PMN. Results from my study suggest that the loss of Ral activity results in secondary granule
release; through secondary granule release, adhesion molecules incorporate into the PMN surface, and thus facilitate PMN migration, interaction with extracellular matrix and communication
with other cells in inflammation.

There are two Ral genes in mammalian cells. The Genebank IDs for RalA and RalB of Homo
sapiens are AF493910.1 and X15015.1, respectively. RalA and RalB are highly homologous,
with about 85% identical amino acids [165] (Figure 1-12). The distinct sequences are mainly located at the carboxyl-terminus, in amino acids 192-204 [166]. RalA and RalB contain the same
amino acid sequences within two effector binding regions, shown in Figure 1-12, suggesting that
they are likely to harbor overlaid functions. As a typical family member of Ras small GTPase, in
the C-terminus, Ral contains an atypical CAAX motif (where C stands for cystein, A stands for
aliphatic amino acid, X stands for methionine or serine); CAAX is a lipid modification motif
[167] and suggests that Ral is likely to be associated with the membrane.

As shown in Figure 1-11, Ral contains two effector binding regions that are also termed “switch
regions”, which mediate the recognition of effectors. Ral performs distinct and important biological functions through interacting with different downstream binding partner proteins. Five
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binding partners have been identified to date. They include RalBP1, Sec5/Exo84 (subunit of exocyst), PLC-δ1, and ZONAB, and phospholipase D 1 (PLD1) [168]. Except for PLD1 binding to
the first 11 amino acids of Ral, others all bind to the switch regions. Through interaction with
diverse effectors, Ral executes different biological functions. Particularly, Ral employs primary
functions in vesicle trafficking through downstream effectors, RalBP1, Sec5/Exo84 and PLD1.

Although Ral engages in many aspects of cellular processes, it executes its major function in exocytosis and endocytosis, mainly by regulating exocyst, which is seen in a variety cell types
[169]. Exocyst is a protein complex composed of Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo70
and Exo84 subunits, and is implicated in the fusion of vesicles to the plasma membrane [170].
The regulation of the exocyst is largely dependent on small GTPases. Ral small GTPases are key
players in this process. A number of publications have demonstrated that Ral promotes exocyst
assembly [171-172]. Using the double-mutant protein Ral23V49N as a probe in the yeast twohybrid system, active Ral was found to directly associate with Sec5, a subunit of exocyst and the
association was confirmed by the decreased formation of exocyst in the absence of Ral [173].

The functions of RalA and RalB are not completely understood. They play a collaborative role in
regulating cytokinesis through exocyst [174], suggesting that RalA and RalB have compensatory
roles in exocytosis. It has been postulated that dense granule releases from permeabilized platelets stimulated with GppNHp, a non-hydrolyzable analog of GTP are triggered by active RalA/RalB [175]. The release of dense granules is abrogated by overexpression of Sec5- GTP-Ralbinding domain (RBD), which suggests the secretion of dense granules from platelets is regulated by the Ral-Exocyst pathway.
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The influence of Ral on vesicle release has also been demonstrated in the neuron signaling system. The expression of a dominant-inhibitory mutant of Ral results in dramatically inhibited release of vesicles in the presynaptic nerve terminal in response to Ca2+. The regulation is likely
through active Ral-exocyst interaction [118]. In addition, active RalA interacts with the mammalian brain exocyst complex [119]. In neuronal cells, chromaffin and PC12 cells, Ral associates
with the plasma membrane in resting cells; however, after stimulation, it is thought to interact
with effector protein(s) and form a complex. Activation of Ral in stimulated PC12 cells by K +
triggers the release of large, dense core secretory granules. Furthermore, overexpression of a
constitutively active form of Ral increases the exocytosis of those granules from PC12 cells
[117].

In polarized epithelial cells, Ral directs vesicle transportation. Protein transportation that was
originally directed only towards the basolateral membrane was changed to the basolateral and
apical membranes in the presence of active Ral [173]. Overexpression of the constitutively active
form of Ral, Ral23V, or the inhibitory construct containing the Ral-binding domain leads to the
inhibition of granule exocytosis in PC12 cells [173]. RalB is required for exocyst complex formation in rat kidney epithelial cells [176]. Active RalA binds exocyst and increases the translocation of E-cadherin in epithelial cells [177]. Adhesion-mediated RalA activation is also required
for integrin-mediated membrane raft endocytosis and recycling during regulation of growth signaling [120].
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In addition to exocytosis, it is reasonable to predict that Ral is also associated with endocytosis,
based on studies demonstrating the function of RalBP1. RalBP1/RLIP76, another important
downstream effector of Ral, is a member of the machinery regulating receptor-mediated endocytosis [121, 178-179]. Using a two-hybrid assay, RalBP1 is found to associate with µ2, the medium chain of AP2 adaptor protein complex [121] that is requisite for clathrin-mediated endocytosis by recruiting clathrin to plasma membrane [180]. Overexpression of constituently active
Ral also blocked endocytosis of transferrin in HeLa cells [121], A431 cells [178], and CHO-IR
cells [178].

Not only does Ral play a crucial role in regulating vesicle trafficking, its functions have also
been explored in tumorigenicity [181]. In human bladder cancer [181], RalA mRNA is significantly upregulated and is associated with invasive tumors. The RalA mRNA level is also highly
associated with cancer protein expression [181]. RalA is required for the growth of human pancreatic carcinoma cells [182]. Also, inhibition of RalB by siRNA resulted in remarkably decreased cell migration in bladder carcinoma and prostate carcinoma cells [183]. RalB is involved
in host defense signaling through suppressing tumor apoptosis, thus leading to cancer cell survival [184-185]. It has been shown that RalB activation promotes the complex formed between
Sec5 and the exocyst subunit, along with TBK1 (Tank binding kinase 1), an atypical IκB kinase
member, resulting in cancer survival.

The effect of Ral in vesicle trafficking has also been elucidated through investigating the function of PLD. PLD1 and its product PA are actively involved in vesicle trafficking, exocytosis and
endocytosis [186-187]. The role of PLD1 is likely to be regulated by ARF6, a small GTPase, due
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to the fact that 1) the activity of PLD1 depends on ARF6, and 2) the inhibition of PLD1 activity
by myr-Arf6 (N-terminal-myristoylated Arf6) [188] peptide leads to impaired exocytosis induced
by calcium in chromaffin cells [189]. PLD1 functions coupled with active Ral are required for
exocytosis. Furthermore, Ral, PLD1 and ARF6 physically associate with each other and form a
complex, mediating exocytosis upon stimulation. The expression of a vector bearing the coding
sequence for active Ral, but lacking in binding sequence for PLD1, fails to elicit granule release,
indicating that Ral functions in concert with PLD1 to modulate exocytosis [117].

The effect of RalA and RalB in PMN is still inconclusive. Using RT-PCR (Figure 3-19), in this
study it was demonstrated that RalA and RalB are both present in human PMN, and RalB is
more dominant than RalA. In my experimental approaches, I utilized a Ral pull-down assay to
investigate the activity switch of Ral. Pull-down assays are widely accepted and used to address
the activity of a variety of small GTPases including Ras, Rac1, Cdc42, Rho, Rap, Arf and Ral.
The assay takes advantage of the specific interaction between RalBP1 and active Ral. It has been
illustrated that amino acids 375-626 of RalBP1 comprise the putative binding domain that mediates the interaction with amino acids 37-56 of RalA [190]. As shown in Figure 1-11 and Figure
1-12, RalA and RalB bear identical amino acid sequences in the binding domain of RalBP1. Although, the Ral pull-down assay was designed originally for the detection of RalA activity, it is
expected that RalBP1 will be able to pull-down the active form of RalB, which has been illustrated in another study [183].

Taken together, the current research is not focused on differentiating the role of RalA and RalB
in regulating secondary granule release in PMN. As shown in Figure 1-11 and Figure 1-12, RalA
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and RalB are highly homologous proteins and share most (if not all) of the functional domains
identified to date. The possible Ral downstream effector proteins relevant to our study involving
in receptor endocytosis, such as RalBP1/RLIP76 [121, 178-179], were found to bind to RalA and
RalB at sites with an identical amino acid sequence (aa 37-56). Given the overlapping functions
of RalA and RalB, and the fact that both of these forms are expressed in PMN, we decided to use
Ral in my study.

In this dissertation, Ral, another family member of small GTPases, is demonstrated to play a vital
role for PMN secondary granule release.
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Figure 1-11. Ral domain structure. The Ral domain structure was adopted from VanDam and
Robinson [168] with modifications using NCBI’s conserved domains software.
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82.1% identity in 206 residues overlap; Score: 855.0; Gap frequency: 1.0%

RalA,

1 MAANKPKGQNSLALHKVIMVGSGGVGKSALTLQFMYDEFVEDYEPTKADSYRKKVVLDGE

RalB,

1 MAANKSKGQSSLALHKVIMVGSGGVGKSALTLQFMYDEFVEDYEPTKADSYRKKVVLDGE
***** *** **************************************************

RalA,

61 EVQIDILDTAGQEDYAAIRDNYFRSGEGFLCVFSITEMESFAATADFREQILRVK-EDEN

RalB,

61 EVQIDILDTAGQEDYAAIRDNYFRSGEGFLLVFSITEHESFTATAEFREQILRVKAEEDK
****************************** ****** *** ***+ ********* *++

RalA,

120 VPFLLVGNKSDLEDKRQVSVEEAKNRAEQWNVNYVETSAKTRANVDKVFFDLMREIRARK

RalB,

121 IPLLVVGNKSDLEERRQVPVEEARSKAEEWGVQYVETSAKTRANVDKVFFDLMREIRTKK
+

*+*+ ********+ +***+ ****++ +** * *+ ************************ +*

RalA,

180 MEDSKEKNGKKKRKSLAKRIRERCCIL

RalB,

181 MSENKDKNGKKSSKN-KKSFKERCCLL
*

+ +*+

*****

*+

*

+ +

****+*

Figure 1-12. Sequence alignment of RalA and RalB. Protein sequence alignment and domain
structures of human RalA and RalB. Alignment of the primary structures of RalA and RalB reveals a high similarity between these proteins. The identical amino acids are indicated by “*” and
the homologous amino acids are indicated by “+”. The different amino acids are highlighted in
purple.
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Summary
This dissertation describes the regulatory function of Ral, a small GTPase, in vesicle trafficking
in the aspect of exocytosis. In particular, my dissertation work investigates the Ral-mediated
complex signaling pathway in the regulation of granule release from a very unique cell type,
PMN. My work, for the first time, reports the novel finding that Ral controls secondary granule
release from PMN (Figure 1-13). Active Ral prevents degranulation of secondary granules from
PMN. The function of Ral as a gate-keeper for secondary granules is further illustrated by overexpression of a constitutively active Ral during PMN chemoattractant stimulation. Inhibition of
Ral activity is intimately related with PMN dysfunction. Thus, my work suggests that Ral is vital
for PMN secondary granule mobilization and is intimately linked to chemotactic function. Regarding the pivotal role of PMN in innate immune response and inflammation, my work will
shed new light on drug design through targeting Ral in PMN in order to defend against a variety
of inflammatory conditions.
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CHAPTER II:
MATERIAL AND METHODS
2.1 PMN isolation
2.1.1 PMN isolation by dextran-ficoll (DEAE-Ficoll)
Human whole blood was drawn from volunteers followed by centrifugation at 200×g for 10 min
and stopped, without breaking, to separate the platelet-rich plasma and blood cells. After decanting plasma, 2% dissolved in 0.9% NaCl was utilized to separate red blood cells (RBC) from leukocytes (35min, 4 °C). The upper layer containing leukocytes were collected into a new tube followed by centrifugation (10min, 4 °C). The 10ml respuspended pellet in 0.9% NaCl was placed
onto 3ml ficoll followed by centrifugation (40min, 4 °C). Pellet on the bottom of the tube was
composed of PMN and RBCs, while peripheral blood mononuclear cells (PBMCs) including
lymphocytes, monocytes and macrophages formed a layer approximately 1ml above the pellet.
After discarding the top solution and the PBMC layer, the pellet containing PMN and RBCs was
resuspended in cold RBC lysis buffer composed of 155 mM NH4Cl, 2 mM NaHCO3 and 0.1 mM
EDTA. After centrifugation, PMN were resuspended in cold HBSS (-) after washing once. PMN
were used within 4 hours of isolation. The purity of PMN isolated using DEAE-Ficoll method
was greater than 95%.

2.1.2 PMN isolation from “buffy coat”
Human whole blood was centrifuged at 1300 rpm for 10 min at 4 °C. After removing the plasma
and top “buffy coat”, a thin layer containing PMN was collected and kept in a new conical tube.
In order to maximally retract PMN from the buffy coat, a thin layer of RBCs underneath the
PMN were also collected and transferred to the same tube. To remove RBCs, two rounds of lysis
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using hypotonic buffer containing 155 mM NH4Cl, 2 mM NaHCO3, 0.1 mM EDTA were applied. After centrifugation, PMN were resuspended in cold HBSS (-) after washing once. The
purity of PMN isolated using this method was about 70% to 80%.

2.1.3. PMN isolation using lympholyte-poly
Human whole blood drawn from healthy donors was added on top of an equal volume of lympholyte-poly (Cedarlane Laboratories Limited) in a 15ml centrifuge tube followed by centrifugation at 500g for 40 min at 25°C. After centrifugation, the RBCs were in the pellet on the bottom
of the tube, while two visible leukocyte bands were formed at 1/3 the length of the tube. The
PBMCs remained at the sample/medium interface (upper band) and the PMN formed a band
(lower band). After removing the upper band containing PBMCs, PMN in the lower band were
harvested into a new conical tube. PMN were washed twice with HBSS (-) without Ca2+ and
Mg2+ followed by centrifugation at 400g for 10 min at 25°C. The PMN pellet was then lysed
once with lysis buffer (Roche, Inc) to remove excessive RBCs followed by centrifugation at
400g for 10 min at 25°C. After centrifugation, PMN were resuspended in cold HBSS (-) after
washing once

2.2 Platelet isolation
Human whole blood was centrifuged at 1000 rpm for 10 min at 4 °C, without breaking, to separate the platelet-rich plasma and blood cells. The top layer containing the platelet-rich plasma
was placed into a new tube. To isolate platelets and prevent activation during the isolation
process, the collected plasma was supplemented with 0.1 volume ACD (2.5% trisodium citrate,
1.5% citric acid, 2% D-glucose) followed by centrifugation at 3000rpm for 15 min. The pelleted
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platelets were washed with a citrate buffer (120mM NaCl, 4.26mM NaH2PO4, 5.5mM glucose,
4.77mM sodium citrate and 2.35mM citritic acid, pH 6.5), and finally resuspended in HBSS (-)
at 4 °C.

2.3 Treatment of PMN with inhibitors and agents
For treating PMN, damnacanthal (Calbiochem) was freshly dissolved in DMSO, followed by further dilution in HBSS(-) at concentrations ranging from 0.1µM to 18µM before incubation with
PMN (5×106 cells) at 25ºC for 15 min. Other inhibitors, such as Bruton tyrosine kinase inhibitor
LMF-A13, Src family inhibitors PP1 and genistein, Syk inhibitor piceatannol, mitogen-activated
protein kinase (MAPK) inhibitor SB203580 and MEK inhibitor PD98059 (all from Biomol), PI3
kinases inhibitor LY294002 (both from Calbiochem) and others, were used as described previously [191-192]. To block the clathrin-mediated endocytosis, dynamin inhibitor dynasore [193]
and an AP-2 binding peptide fragment of the EGFR protein tyrosine kinase substrate #15
(Eps15-DIII) [194-195] were used as previously described. Eps15-DIII was delivered into PMN
by tagging with HIV Tat. PMN were pre-treated with these reagents for 5-15 minutes before stimulation with 1µM fMLF at 37°C.

The endocytosis inhibitors phenylarsine oxide (POA) and chlorpromazine hydrochloride (CPZ)
[196] were purchased from Sigma and freshly prepared prior to the study. POA was dissolved in
DMSO followed by dissolving in HBSS (+) at the final concentration of 20µM, followed by incubation with PMN (1.5x 107) at 37ºC for 5 min before fMLP stimulation. DMSO, at a final
concentration of 0.06%, was used as the vehicle control for POA. CPZ, sucrose (Thermo Fisher
Scientific, Inc), NaCl (Thermo Fisher Scientific, Inc), and succinic acid pH 5.5 (Thermo Fisher

48

Scientific, Inc) [197-198] were dissolved in HBSS (+) at a final concentration of 50µM,
500mM, 760mM and 20mM, respectively, followed by incubation with PMN (1.5x 107) at 37ºC
for 5 min.

2.4 PMN degranulation assays
To test the effect of inhibitors on resting PMN, PMN (5×106) were incubated in 400µl of HBSS
(-) with different inhibitors or the same dilution of DMSO at 25ºC for 15 min followed by centrifugation. Clear supernatants without cell debris were collected and assayed for specific granular
markers including myeloperoxidase (MPO), lactoferrin and gelatinase correlating to the release
of primary, secondary and tertiary granules, respectively [69, 191]. MPO activity was assayed
using 2, 2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid (ABTS). Lactoferrin was assayed by
ELISA using anti-lactoferrin antibody (Jackson ImmunoResearch Laboratories). Gelatinase was
assayed by zymogram using gelatin-embedded gels (BioRad).

To assay degranulation after chemoattractant stimulation, PMN, untreated or treated with Tattagged peptides, PMN (2.5 x 106) were incubated with purified Tat-tagged wild-type Ral (Ral),
the constitutive active form (RalG23V) and dominant negative form (RalS28N) of RalA at concentrations of 10nM and 40nM for 15 min at 15°C followed by stimulation in 250µl HBSS (+)
with fMLP (1µM) for 20 min at 37ºC. Following a similar procedure, supernatants without cell
debris were collected and assayed for the release of granular markers. To assay PMN degranulation after treatment with endocytosis inhibitors, PMN (1.5 x107) were incubated in 1.2ml HBSS
(+) with different inhibitors at 37ºC for 5 min followed by fMLP (1µM) stimulation at 37ºC for
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10 min followed by assaying for the release of granular markers. Positive degranulation controls
were performed by stimulating the same amount of PMN with fMLF plus 10µM CB [135].

2.5 PMN transmigration assay
PMN migration across collagen-coated transfilters was performed as described previously [69,
191]. Briefly, freshly isolated PMN (1 × 106), non-treated or treated with inhibitors (15 min,
25oC) or Tat-tagged Ral peptides (30 min, 4oC) at final concentration of 10nM and 40nM were
loaded into the upper chambers of the transmigration setups in 150μl HBSS (+). Transmigration
was initiated by adding 0.1μM fMLF in the lower chambers containing 500μl HBSS (+) and incubation at 37°C. PMN that migrated into the lower chambers were quantified by measuring the
activity of myeloperoxidase (MPO), a marker for primary granules. MPO was released by lysing
plasma membrane using Triton X-100. 25μl 10% Triton X-100 was added to the lower chamber
containing migrated PMN at a final concentration of 5%. 25μl 1M citrate buffer pH 4.2 was also
added to the lower chamber to adjust the pH to 4.2. Equal amounts of sample were mixed with
the solution containing 1 mM ABTS, 10 mM H2O2, and 100 mM citrate buffer pH 4.2. Color
matrix was developed at 405nM on a plate reader. In order to quantify the number of the migrated cells in the lower chamber, a standard curve was also generated using known concentrations of PMN.

2.6 Ras family GTPase activation assay
Ras GTPases activation assay in PMN
The GTPase activities of Ras, Rap and Ral in PMN were assayed using Ras, Rap and Ral activation assay kits (Millipore) with modifications. Briefly, PMN (2×107 cells/per condition) or plate-
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lets (3×108 cells/per condition), with or without different treatment, were lysed with a buffer containing 25mM Hepes, pH7.5, 150mM NaCl, 2mM MgCl2, 1% NP-40, 0.5% Na deoxycholate,
1% Triton X-100, 2% glycerol and protease inhibitors (cocktail (Sigma) and 10mM PMSF) followed by incubation with Raf-1 RBD, RalGDS-RBD or RalBP1 (residues 397-519 of rat
RalBP1)-conjugated agarose for 45 min at 4°C. After washing the agarose, the pulled-down active Ras, Rap and Ral were detected by Western blot. Positive and negative controls were performed by addition of GTPγS or GDPγS to the cell lysates before pull-down. In addition, whole
lysates from both control and treated cells were saved and run in parallel, serving as an internal
loading control to determine the total amount of Ras, Rap and Ral proteins.

Alternatively, active Ral in PMN was also pulled down using a RalBP1 of human origin (amino
acids 397-518 of human RalBP1) and GST fusion protein, a gift from Dr. Johannes Bos (Utrecht
University, Netherlands) [163]. Our results indicated that RalBP1 of either human or rat origin
worked equally well to pull down active human Ral.

Ral GTPases activation assay in platelets
Fresh isolated human platelets (3 × 108 cells/per condition) with or without thrombin stimulation
were subjected to the Ral activation assay. Isolated platelets were stimulated with human recombinant thrombin (Sigma, Saint Louis) at a final concentration of 0.1UN/ml in tissue culturetreated 6-well plates (Costar, Corning Incorporated) at 37°C for 20 min. Cells were lysed in the
buffer containing 25mM Hepes, pH 7.5, 150mM NaCl, 1% NP-40, 1% Triton, 2% glycerol,
0.5% Na-deoxycholate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF. After centrifugation, the cleared supernatant was incubated with 30 µg GST-RalBP1 (human sequence) fu-
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sion protein-coupled glutathione-sepharose with gentle agitation for 1 hour at 4°C to pull down
the active form of Ral. The sepharose mixture was pelleted down, washed with lysis buffer. Active Ral was detected by western blot using an anti-Ral antibody. In addition, whole cell lysates
from unstimulated and stimulated platelets were saved and applied to western blots to assay the
total Ral proteins.
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Figure 2-1. GTPase pull down assay
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2.7 Generation of HIV Tat-tagged recombinant proteins
A GST gene fusion system was used to express and purify Ral and Eps 15-DIII fusion proteins in
Eschericia coli. Three pGEX-5X1 vectors expressing the full length (wild-type), the constitutive
active form (G23V) and dominant negative form (S28N) of Ral protein were constructed (Figure
2-2). For Eps15, two constructs expressing Eps15-DIII with the binding ability to AP-2 and
Eps15-Δ without the binding ability to AP-2 were obtained.

2.7.1 Generation of HIV Tat-tagged Ral recombinant proteins under soluble conditions
Briefly, to generate Tat-tagged Ral proteins, the entire cDNA of wild-type Ral was RT-PCR amplified from leukocytes (Marathon Ready cDNAs, Clontech) using a sense primer, 5’- atatggatcccctacggccgcaagaaacgccgccagcgccgccgcatggctgcaaataagcccaagggt, (underlined) coding for
the 11 residues of HIV Tat (YGRKKRRQRRR) [199-201], and an antisense primer, 5’atatctcgagttataaaatgcagcatctttc, followed by cloning into pGEX-5X1 vector through BamHI and
XhoI site, respectively. To produce the constitutively active (Ral23V) and dominant-negative
(Ral28N) mutants [117, 167, 202], Gly23 and Ser28 in wild-type Tat-Ral were mutated to Val
and Asn, respectively, using GeneTailor™ Site-Directed Mutagenesis kit (Invitrogen, USA). After production of the recombinant proteins, GST within the fusion was removed by Factor Xa
(New England Biolabs) and the obtained Tat-tagged Ral and Eps15 proteins were obtained followed by filtering through 0.22μm filters. To label peptides with fluorescein (FITC), an EZLabel FITC protein labeling kit (PIERCE) was used. For transduction into PMN, Tat-tagged pro-
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teins (10-100nM) were directly incubated with freshly isolated PMN in HBSS (-) for 10-30 min
at 4°C.

Considering the high possibility of protein precipitation due to the positive charge of HIV-Tat,
the HIV-Tat-tagged protein is commonly purified under denatured conditions. Given that PMN
are very prone to be activated, the common procedure for protein expression and purification of
HIV-Tat-tagged protein was modified in this research.

2.7.1.1 Induction and purification of GST-Tat-Ral fusion protein
Followed by transformation to E. coli BL21 cells, GST fusion protein expression was induced by
IPTG (isopropyl-beta-D-thiogalactopyranoside). In order to obtain high level of protein expression and prevent protein formation into inclusion body, the induction environment was modified
before large-scale protein induction. Bacteria growth to the saturate status was required, and
OD600 was measured to be 0.8 before IPTG induction.

Wild-type Ral protein was induced by IPTG at a final concentration of 0.5mM at 20°C with constant shaking overnight. While, the final concentration of IPTG for inducing mutant forms of Ral
was decreased to 0.1mM due to the fact that under the same induction condition, protein expression levels of the constitutively active form (G23V) and dominant negative form (S28N) of Ral
were very low compared with that of wild-type protein. In order to increase protein expression
level, the final concentration of IPTG was decreased to 0.1mM to prevent protein aggregation in
the inclusion body.
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After IPTG induction and centrifugation, cell pellet was resuspended in 1× ice cold PBS, followed by sonication. A clear cell lysate was obtained after centrifugation at 15000rpm for 10 min
at 4°C. GST fusion proteins were purified by affinity purification using glutathione-sepharose 4B
(Amersham Biosciences). Glutathione-sepharose was incubated with the clear lysate with gentle
agitation for 2 hours at 4°C. According to the binding capacity that 1 ml drained glutathionesepharose is able to bind 8 mg fusion protein, a sufficient amount of glutathione-sepharose was
added to the lysate. Medium mixed with cell lysate and sepharose was then packed into column
(Pierce) followed by washing with 500 ml 1× ice cold PBS and eluted with10mM reduced glutathione in 50mM Tris pH 8. The eluted protein was then concentrated using Millipore Amicon
Ultra-4 10,000 mwco to the final concentration of approximately 0.6 mg/ml, followed by dialysis
against 1×PBS by using dialysis tubing (Spectrum Spectra, 12-14,000 mwco). In order to prevent
activation of the protein precipitation cascade, protein concentration was modified below 1
mg/ml, and several rounds of high speed centrifugation were required to remove any small precipitants before dialysis. After dialysis and sterilization through 0.2µm filter, protein purity was
analyzed by coomassie blue staining and western blot.

2.7.1.2 Cleavage of GST-Tat-Ral fusion protein
In order to obtain Tat-Ral proteins, GST-tag was cleaved from GST fusion protein by Factor Xa
(NEB). Briefly, GST fusion proteins were incubated with Factor Xa at 0.3µg Factor Xa to 25 µg
GST fusion protein at 25°C for 2.5 hours followed by incubation with glutathione-agarose with
agitation at 4°C for 4 hours. The Tat-Ral protein in the run-through was obtained after passing
protein mixture through the column (Pierce). Purity was then analyzed by coomassie blue staining. In particular, before cleavage, GST fusion protein concentration was adjusted below 1mg/ml
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to prevent Tat-Ral protein precipitation during cleavage, likely due to the exposure of highly
charged amino acids.

2.7.2 Generation of HIV Tat-tagged Eps15 recombinant proteins under soluble conditions
The same approach of generation and purification of HIV Tat-tagged Eps 15 protein as HIV Tattagged Ral protein was applied. Two Tat-tagged Eps15 C-terminal peptides were produced, the
AP-2 -binding peptide (amino acids 563-885, designated as Eps15-DIII) and non-binding peptide
(amino acids 740-885, designated as Eps15-Δ) [194-195]. To construct these proteins, RT-PCR
were performed using an antisense primer, 5’-tagccagttctaagtcttc, and Tat sequence-containing
sense primers, 5’-atatggatcccctacggccgcaagaaacgccgccagcgccgccgccctgaactactgccttctggtgtga
and 5’-atatggatcccctacggccgcaagaaacgccgccagcgccgccgctcagccacatcgagctctgtcagcaac, respectively. HIV Tat-tagged Eps15 protein was expressed and purified in the same way describe in
2.7.1.
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Transformation of pGEX-5X1-TatRal vector to BL-21 cells
YGRKKRRQRRR
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Figure 2-2. HIV-Tat-Ral expression and purification system. A) pGEX-5X1-Tat-Ral expression
vector. B) Structure of GST-Tat-Ral protein. There were three pGEX-5X1 vectors expressing
the full length (wild-type), the constitutive active form (G23V) and dominant negative form
(S28N) of Ral protein. After Factor Xa cleavage, GST-tag was removed from Tat-Ral peptide.
C) Detailed Tat-Ral protein expression and purification workflow
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2.8 Zymogram assay
Gelatinase activity was assayed by gelatin zymography (Bio-Rad, Inc). Briefly, the clear supernatant was mixed with non-reducing SDS gel sample buffer and subjected to a gelatin gel with
10 μg protein per lane. The gel was then washed twice in 2.5% TritonX-100 in 50 mM Tris pH
7.4, 5 mM CaCl2, 1 microM ZnCl2 at 25°C followed by incubation in the same buffer without
Triton X-100 at 37°C for 20 h. The polyacrylamide gel was then stained with coomassie blue R250 for 1 hour at 25°C followed by destaining for 30 min at 25°C . Gelatinase activity was
shown by the white areas of loss of coomassie blue staining.

2.9 Subcellular fractionation of PMN
Freshly isolated PMN (108/per condition), with or without fMLF stimulation or inhibitor treatment, were lysed in a buffer containing 25mM Hepes pH7.5, 150mM NaCl, 10% sucrose, 2mM
MgCl2 and protease inhibitors using a dounce homogenizer followed by centrifugation at 200×g
for 5min. Meanwhile, discontinuous sucrose density gradients were prepared by layering 5 layers
of successive decreasing sucrose density solutions (5ml/layer) upon one another (60%, 50%,
40%, 30% and 20%). PMN lysates (10ml) were then layered on top of the gradients. After centrifugation with a Beckman SW28 swinging bucket ultracentrifuge rotor for 3h at 28, 000rpm
(141,000×g) (4°C), the gradients were fractionated (1ml/fraction) followed by analysis for plasma membrane (alkaline phosphatase), primary granule (myeloperoxidase), secondary granule
(lactoferrin) and tertiary granule (gelatinase) [69-70].
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2.10 FITC Protein Labeling
Tat-tagged Ral protein was fluorescently labeled using EZ-Label™ FITC Protein Labeling Kit
(PIERCE). Briefly, Tat-tagged Ral proteins were dialyzed against BupH Borate buffer containing 50 mM borate, pH 8, using Slide-A-Lyzer MINI Dialysis Unite with 3500 MWCO (PIERCE)
for 1 hour at room temperature to exchange protein buffer for optimizing protein labeling. After
buffer exchange, FITC was added into protein according to the formula* and incubated at room
temperature for 1 hour. FITC-protein mixture was then dialyzed against 1×PBS at 25°C for 1
hour in the same dialysis unit to remove excess fluorescent dye followed by transduction to
PMN.

microliters of FITC solution to add to labeling reaction=

Simplified formula*:

mmol
ml protein

24mmol

389

100µl

mmol

1mg

protein concentration
Xmg

Xmg

X=Molecular Weight of the protein

2.11. Immunofluorescence labeling and flow cytometry
Fresh isolated PMN (5 × 106) were pretreated with tyrosine kianses and other pharmacological
inhibitors in HBSS (-) for 10 min (20°C). After centrifugation at 1300rpm for 5 min at 4°C, the
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cell pellet was resuspended with blocking buffer containing 0.5% BSA. Cell surface expression
of CD11b, CD47 and SIRPα was assessed by labeling non-permeabilized PMN with anti-CD11b
mAb LM2/1, anti-CD47 mAb B2H6 and anti-SIRP antibodies (10µg/ml each, 1h, 4°C), respectively. After washing, PMN were briefly fixed with 3% paraformaldehyde (PF) for 5 min at 25°C
followed by incubation with fluorescence conjugated secondary antibodies (1:1000 dilution in
blocking solution) for 30 min. Cells were observed under confocal microscope (Zeiss) or analyzed by flow cytometry (BD). Cell surface labeling by various antibodies was compared with
that obtained with isotype-matched control IgG. For intracellular localization staining, cells were
fixed with 3% PF and then permeabilized by 0.03% Triton X-100 for 10 min at 4oC before antibody labeling. For plasma membrane labeling, cells were incubated with wheat germ agglutinin
(WGA) at the final concentration of 5 μg/mL for 1 min at 25 oC followed by washing with HBSS
(-).

2.12. Other reagents
Hybridoma cell line that produces anti-CD11b antibody LM2/1 was obtained from the American
Type Culture Collection (ATCC). Monoclonal antibody against the extracellular domain of
CD47 (PF3.1) was generated previously [69]. Rabbit polyclonal antibodies against the extracellular domains of SIRPα (anti-SIRPα.ex) and JAM-A (anti-JAM-A.ex) were raised by immunizing rabbits with purified fusion proteins comprised of rabbit Fc and the entire extracellular domains of SIRPα or JAM-A[87, 203]. Antibodies against Ral, Ras and Rap1 were purchased from
Millipore. Anti-β actin mAb was purchased from Sigma. Rabbit anti-α-adaptin was purchased
from Santa Cruz Biotechnology. Rabbit anti-RalGDS was purchased from EMD Millipore.
Alexa Fluor 594 conjugated WGA was purchased from Invitrogen.
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2.13 Statistical analyses
All the data was analyzed using Prism software. P value for statistical significance was below
0.05.
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CHAPTER III:
CONTROL OF SECONDARY GRANULE RELEASE IN
NEUTROPHILS BY RAL GTPASE
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Introduction
Neutrophils, or polymorphonuclear leukocytes (PMN), occupy the largest population in
peripheral leukocytes and play a crucial role in innate immunity. During acute infection and
inflammation, PMN sense chemoattractant signals and swiftly migrate across the
microvasculature and underlying tissues to accumulate at inflammatory foci, where these cells
execute forceful antimicrobial and tissue damaging functions. Therefore, the timely and precise
response of PMN constitutes an essential first-line defense against invading microbial. On the
other

hand,

PMN-mediated

inflammation

is

also

a

central

component

of

many

pathophysiological processes and diseases in which dysregulated PMN transmigration and
activation often result in severe tissue injuries and organ dysfunction [25, 96]

Different from most of other cell types, PMN contain a highly granular cytoplasm. At least four
types of granules and vesicles have been classified in PMN including peroxidase-positive
primary granules (also termed azurophil granules), peroxidase-negative secondary and tertiary
granules (also termed as specific and gelatinase granules, respectively), and a group of highly
mobilizable secretory vesicles [61-62]. These various granules and vesicles in PMN constitute an
important reservoir of antimicrobial peptides, proteases, respiratory burst oxidases, as well as
many membrane-bound receptors and adhesion molecules. PMN functions in response to
inflammatory stimuli are largely dependent on the mobilization and release (degranulation) of
these cytoplasmic granules and vesicles. In general, the secretory vesicles are highly mobilized
for extracellular release. These vesicles provide the PMN cell surface with essential, but low
levels of receptors and molecules that are important in PMN sensing and triggering activation
[61-63]. Upon chemoattractant stimulation, secondary and tertiary granules are released, and this
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vital degranulation process enables PMN to adhere to and migrate across vascular endothelium
and tissue layers [26, 61-64]. PMN secondary granules contain a large number of key cell
adhesion molecules, such as the β2 integrin CD11b/CD18 [66-67] and the Ig superfamily
members CD47 and SIRPα [68-70], all of which are required for PMN adhesion and chemotaxis.
Degranulation of secondary granules also releases the anti-pathogen protein lactoferrin. Tertiary
granules have a high content of gelatinases; release of these collagenolytic metalloproteases
plays a critical role in degradation of the extracellular matrix during PMN extravasation. In
addition to these granules / vesicles, studies have also found that certain primary granules are
also released during PMN activation and that some of the primary granule components, such as
elastase, are indispensable for PMN migration in the tissues.

The molecular mechanisms that control PMN degranulation are, however, still unclear. The signaling events elicited by chemoattractant stimulation leading to PMN degranulation of each type
of granule are complex, and only inadequately understood. In other cell types, Ras family small
GTPase Ral has been shown to be required in intracellular vesicle transportation, including both
endocytosis and exocytosis [117-121]. Here, we report our experimental findings which reveal
for the first time that Ral controls PMN release of secondary granules. In particular, our studies
suggest that active Ral serves as an essential gatekeeper which prevents secondary granule release. Disruption of Ral regulation, either by inhibition of Ral activity in resting PMN or overexpression of a constitutively active Ral during chemoattractant stimulation, results in dysregulation of secondary granule mobilization and impairment of PMN chemotactic function.

Results
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Ras family inhibitor damnacanthal triggeres release of PMN secondary granules.
PMN surface adhesive proteins, such as CD47 [69, 71], CD11b/CD18 [66-67] and SIRPα [68,
204], play important roles in PMN adhesion, transmigration and phagocytosis. Instead of being
constitutively expressed on the cell surface, these essential proteins are mainly stored in intracellular granules under resting conditions, but are rapidly upregulated onto the cell surface in response to inflammatory chemoattractants following the process of PMN degranulation [69-70].
To reveal the mechanisms involved in control of PMN storage of these important cell surface
proteins and PMN degranulation, a panel of pharmacological probes / inhibitors targeted different signaling molecules and pathways were tested for their effects on the cell surface protein expression. Treatment of PMN with damnacanthal, a membrane-permeable inhibitor of the Ras
family GTPases and the Src family tyrosine kinase Lck [205-207], was found to result in a dramatic increase of CD11b/CD18, CD47 and SIRPα on the PMN cell surface despite the lack of
chemoattractant stimulation. As shown in Table 1, after damnacanthal treatment, FACS analysis
showed increases of the mean fluorescence intensities (MFI) of cell surface CD11b/CD18, CD47
and SIRPα labeling from the basal level of 90.7, 35.2 and 14.2 up to 203.8, 112.8 and 67.8, respectively. In contrast, treating PMN with the vehicle control or other inhibitors, such as genistein, piceatannol, LFM-A13, PP1, PD98059, LY294002 and others, did not change the levels of
these proteins on PMN cell surface. Analysis of the cell shape and/or sizes by FSC and SSC parameters also indicated a visible shift of the PMN population towards lower FSC/SSC after damnacanthal treatment (data not shown), suggesting a potential of PMN degranulation.

Since PMN contain multiple types of intracellular granules, and CD47, CD11b/CD18 and SIRPα
are mainly stored in secondary granules [69-70], it was thus highly possible that increase of these
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proteins on the cell surface by damnacanthal treatment was through PMN degranulation. Therefore, the release of primary, secondary and tertiary granules after damnacanthal treatment was
analyzed. As shown in Figure 3-1, compared to other inhibitors that did not cause PMN degranulation, damnacanthal dose-dependently induced PMN release of secondary granules. In contrast,
no apparent release of primary or tertiary granules was observed by treating PMN with damnacanthal. In the experiments, PMN were also treated with chemoattractant fMLF and a combination of fMLF and actin filament disruption reagent cytochalasin B (CB) to serve as positive degranulation controls [135]. As shown in Figure 3-1, as predicted, treating PMN with only fMLF
resulted in significant degranulation of secondary and tertiary granules, but not primary granules,
while treatment with fMLF-CB combination induced a robust and complete degranulation of all
the granules. At a concentration of 18μM, damnacanthal treatment could generate amounts of
lactoferrin release comparable to the combined fMLF and CB treatment, indicating a nearly
complete degranulation of secondary granules (Figure 3-1). In conclusion, these studies found
that treatment of PMN with damnacanthal selectively induced the degranulation of secondary
granules.
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Table 1. Damnacanthal treatment induces an upregulation of CD11b/CD18, CD47 and SIRPα on
PMN surface.
Effects of pharmacological inhibitors on PMN cell surface protein expression

PMN surface mean fluorescence intensity (MFI)
Inhibitors

Ctl IgG

CD11b/CD18

CD47

SIRPα

Vehicle ctl (DMSO)

3.2±0.08

90.7±0.11

35.2±0.038

14.2±0.09

Damnacanthal (10µM)

2.5±0.18

203.8±0.22

112.8±0.19

67.8±0.16

Genistein (100µg/ml)

4.3± 0.13

76.6±0.28

30.0±0.13

19.6±0.14

Piceatannol (40µM)

5.5±0.26

94.0±0.17

28.2±0.14

13.5±0.16

PP1 (18µM)

2.7±0.33

85.2±0.43

29.3±0.46

11.6±0.31

LFM-A13 (140µM)

4.4±0.51

89.3±0.44

28.5±0.69

9.7±0.42

Herbimycin A (2µM)

5.2±0.26

95.7±0.25

30.3±0.15

16.3±0.45

Lavendustin A (10µM)

5.5±0.16

91.4±0.32

32.2±0.21

20.1±0.25

Erbstatin analog (25µM)

4.8±0.17

81.6±0.20

29.8±0.19

18.3±0.23

SB203580 (1µM)

6.1±0.30

83.8±0.40

28.8±0.15

15.2±0.23

PD98059 (80nM)

3.7±0.16

89.9±0.24

26.7±0.18

12.5±0.25

LY294002 (100nM)

3.0±0.14

79.6±0.13

31.9±0.30

19.1±0.15

AG126 (150µM)

4.3±0.17

97. ±0.19

30.7±0.14

14.6±0.24

Table 1. In these experiments, freshly isolated PMN (5×106) were incubated with damnacanthal
or other inhibitors in their working concentrations for 15min at 25°C. After blocking with 5%
normal goat serum, PMN cell surface CD11b, CD47 and SIRPα were labeled with LM2/1, PF3.1
(10µg/ml each) and anti-SIRPα.ex (1:2000 dilution), respectively, for 1h (4oC). After washing
and fixation with 3% paraformaldehyde (5min, 20oC), cells were incubated with Alexa Fluorconjugated secondary antibodies followed by washing and analysis by flow cytometry. PMN labeled with normal mouse IgG served as baseline. The table shows the mean fluorescence intensity ±SEM. SEM: SD divided by the square root of the sample size.
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Figure 3-1. Damnacanthal treatment induces specific release of PMN secondary granules. Freshly isolated PMN were treated with damnacanthal (Damn) of varied concentrations and other inhibitors for 15min at 25°C. A control treatment was performed using vehicle (DMSO) of the
same dilution (0.1%). After centrifugation to pellet cells, PMN degranulation was assessed by
assaying different granular markers in the cell-free supernatants. Positive degranulation controls
were performed by stimulation of PMN with 1µM fMLF with and without an addition of 10µM
cytochalasin B (CB). Concentrations of LY94002, Piceatannol, SB203580, genistein and
PD98059 used in the treatment were the same as those in Table 1. A) Assaying secondary granule release by measuring lactoferrin in the supernatants. B) Assaying primary granule release by
measuring MPO activity in the supernatants. C) Assaying tertiary granule release by zymogram
detecting gelatinase in the supernatants. The arrows indicate the two major forms of gelatinase
(92kD and 56kD, respectively) in PMN. As shown, damnacanthal (Damn.) specifically and dosedependently induced secondary granule degranulation. Data (mean ± SD) represent more than
five independent experiments. Significant degranulation was marked by “*”.
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Damnacanthal treatment results in defect of PMN function.
In general, PMN degranulation of secondary granules is triggered by chemoattractants binding to
the cell surface receptors followed by signaling relays involving G protein and a series of downstream signaling molecules [208]. Since damnacanthal caused release of secondary granules in
the absence of chemoattractant stimulation, I questioned whether this kind of “dysregulated” degranulation would affect PMN function and thus assayed chemoattractant-induced PMN transmigration and adhesion/spreading. As shown in Figure 3-2, in contrast to that PMN vigorously
transmigrated towards fMLF in the control condition, damnacanthal dose-dependently inhibited
PMN transmigration and completely abolished PMN migration at a concentration of 18μM. Also
as shown in Figure 3-3A, compared to control PMN which responded to fMLF stimulation and
quickly spread on collagen-coated surfaces displaying a polarized F-actin labeling pattern, damnacanthal treatment impaired PMN spreading. Indeed, PMN adhesion to collagen induced by
fMLF was significantly weakened in the presence of damnacanthal (Figure 3-3B). Next I examined whether damnacanthal treatment affected cell surface protein function. Since CD47 and
SIRPα are extracellular counter-ligands [68, 87], we thus tested cell surface CD47 direct binding
to a SIRPα extracellular domain fusion protein, SIRPα1.ex-Fc [70, 87]. As shown in Figure 3-4,
although damnacanthal induced a significant increase of CD47 on PMN cell surface, these upregulated CD47 were not binding to its ligand SIRPα. In contrast, CD47 was also increased on
PMN surface after fMLF stimulation, and these CD47 directly bound to SIRPα1.ex-Fc (Figure 34).
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Figure 3-2. Damnacanthal inhibits chemoattractant-triggered PMN function. A) Damnacanthal
inhibits PMN chemotaxis. PMN (106) were treated with damnacanthal of varying concentrations
for 15min at 25°C followed by assaying transmigration across collagen-coated filters towards
fMLF (0.1µM) in 1h. Data (mean ± SD) represent three independent experiments with triplicates
in each condition (*, p<0.05, **, p<0.01).
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Figure 3-3. Damnacanthal inhibits chemoattractant-triggered PMN function. Damnacanthal inhibits PMN F-actin polarization (A) and spreading (B). PMN (106), untreated or treated with
damnacanthal (10 µM), were stimulated with fMLF (1µM, 37°C) in collagen-coated wells followed by observation of PMN adhesion and spreading (phase-contrast images). After stimulation
for 20min, the cells were then fixed and permeabilized followed by labeling F-actin with rhodamine-conjugated phalloidin.
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Figure 3-4. Damnacanthal inhibits chemoattractant-triggered PMN function. Cell surface CD47
binding to SIRPα. An extracellular domain fusion protein, SIRPα1.ex-Fc, was used to test PMN
cell surface CD47 binding after treatment with either fMLF (1µM) or damnacanthal (10µM). Total amount of CD47 on cell surface was confirmed by labeling non-permeabilized cells with antiCD47 mAb PF3.1.
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Identification of the specific GTPase associated with secondary granule release.
Efforts have been made to identify the target molecule of damnacanthal that plays an important
role in preventing secondary granule release in PMN prior to chemoattractant stimulation. We
have found that, although damnacanthal is a potent inhibitor of the tyrosine kinase Lck, its effect
on PMN degranulation was not through targeting Lck. In agreement with many studies by others,
I observed that Lck is mainly expressed in T cells but not in PMN (Figure 3-5). In addition, Dr.
Liu obtained Lck-knockout mice [209] from Dr. Tak Mak (Ontario Cancer Institute, Canada).
Comparing PMN isolated from Lck knockout mice with the cells from their wild-type littermates
yielded no difference in the levels of cell surface protein expression, PMN response to chemoattractant stimulation, degranulation and chemotactic transmigration (data not shown), suggesting
that Lck is dispensable in PMN function. A previous study by Brumell et al. also indicated no
Lck activity in PMN[210]. In addition to Lck, damnacanthal is also an established inhibitor of
Ras family small GTPases [206-207]. Since some of these GTPases, such Ras family member
Ral, have been demonstrated to play important roles in vesicle transportation, thus it was likely
that the effect of damnacanthal on PMN through inhibition of Ras family members.

The Ras family small GTPases are traditionally classified into three major subfamilies, Ras (H,
R, etc.), Rap (1/2) and Ral (A/B) [211-213]. In addition, three new members of Ras family small
GTPases have been identified recently including Rheb, Rin, and Rit [214]. To identify which is
potentially involved in the degranulation of secondary granules, I screened the Ras members for
activity changes before and after chemoattractant stimulation. Given that damnacanthal treatment
caused secondary granule release in the absence of stimulation, I speculated that the candidate
Ras member must be in its active form in resting PMN. Also, since chemoattractant stimulation
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triggers secondary granule release, we reasoned that this specific Ras should be deactivated in
order to coordinate secondary granule release. Based on this rationale, I assayed the activities of
Ras, Rap and Ral in PMN before and after fMLF stimulation, and with or without damnacanthal
treatment. As shown in Figure 3-6, Ras, Rap and Ral were all expressed in PMN. Among the
three family members, Ras was found mainly in its inactive form in unstimulated PMN and was
quickly activated after fMLF stimulation. Rap, on the other hand, showed minor activity changes
before or after fMLF stimulation and, to our surprise, was insensitive to damnacanthal treatment
(Figure 3-6). Therefore, neither Ras nor Rap was likely the candidate that regulates secondary
granule release.

In contrast to Ras and Rap, Ral demonstrated a dynamic activity change that correlated with
chemoattractant stimulation and PMN degranulation. As shown in Figure 3-6, Ral appeared to be
in its active form in unstimulated PMN, and quickly became inactive following fMLF stimulation. Pull-down experiments using RalBP1, a downstream effector that specifically binds to active Ral, recovered significant amount of active Ral from resting PMN. On the other hand, stimulation with fMLF resulted in a quick diminishing of RalBP1 pull-down within 2-5min, a time
course paralleled with secondary granule release that was assayed simultaneously (Figure 3-6,
right). Same results of were obtained when PMN were stimulated by another chemoattractant IL8 (Figure 3-7). Deactivation of Ral was also observed in PMN that had chemotactically transmigrated across collaged-coated filters towards fMLF (Figure 3-6, migrated). In addition, activity
of Ral in resting PMN was inhibited after damnacanthal treatment (Figure 3-6), which correlated
with damnacanthal-induced secondary granule release. Thus, these results suggested Ral to be
the regulator that controls secondary granule release in PMN.
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Figure 3-5. Lck is not expressed in neutrophils (PMN). A) Western blot detecting Lck in PMN
and PBMC. B) Immunofluorescence labeling demonstrating that Lck is expressed in SIRPαnegative cells in PBMC, mainly lymphocytes, but not in SIRPα-positive monocytes or PMN.
(Antibody against Lck was purchased from Cell Signaling Technology.) Note: SIRPα is restricted in myeloid lineages, including PMN, monocytes and dendritic cells, but not expressed in
lymphocytes. Few Lck-positive cells detected in isolated PMN were likely due to an unavoidable
contamination of PBMC. In general, PMN are separated from PBMC by Ficoll-Paque density
gradient (used for this study) or gelatin sedimentation. The former method normally produces
PMN of 90-95% purity while the latter method produces PMN of varied purity, between 7090%. Expression of Lck in eosinophils was also reported (Stafford et al. The Journal of Immunology, 2002; Lynch et al. Blood, 2000) and may account for few Lck-positive cells in the preparation of PMN.
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To further explore the mechanism that regulates Ral activity in PMN, the localization of RalGDS
in PMN was investigated (Figure 4-1). The effect of Ca2+ and Mg2+ on Ral activity was examined (Figure 4-2, 4-3, 4-4). Results showed that Mg2+ was the potential regulator in controlling Ral activity.

To confirm my studies in PMN and verify the pull-down assays, in parallel experiments, I simultaneously assayed Ral activity in platelets. As shown in Figure 3-7B, RalBP1 pull-down results
agreed with the previous report by others showing that Ral is inactive in resting platelets and
activated after thrombin stimulation [163]. The different Ral activity profiles in PMN and platelets thus suggest that these cells employ distinctive signaling mechanisms to regulate Ral activity
and that Ral may have different functional aspects in PMN and platelets.

In addition, Ral activity was also assayed in PMN isolated directly from the “buffy coat” (Figure
3-8) or isolated using lympholyte-poly (Figure 3-9, Figure 3-10) to further investigate the effects
of Ral activity on PMN secondary granule release.

Comparing PMN isolated using DEAE-DEXTRAN with the cells isolated from the “buffy coat”,
Ral demonstrated the same activity profile. As shown in Figure 3-8, Ral was in its active form in
unstimulated PMN, and became inactive following fMLF stimulation.

Ral in PMN isolated using commercial separation chemical, lympholyte-poly, however, retained
minimal activity in unstimulated cells (Figure 3-9 and Figure 3-10). fMLF stimulation (Figure 39) rendered a quick activation of Ral within 1 min, and a prompt diminishment of Ral activity
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after 1 min. IL-8 stimulation (Figure 3-10), on the other hand, sustained Ral activity until 10 min,
followed by the loss of activity after 15 min. The similar observation that Ral was inactive in unstimulated PMN was reported by another group [215]. The variation of Ral activity in unstimulated PMN was likely due to the distinct isolation method. In my study, I employed three isolation approaches to examine the activity of Ral in PMN before and after chemoattractant stimulation. Ral was only shown to be inactive in PMN isolated using lympholyte-poly. The results suggest that PMN isolated using DEAE-DEXTRAN may not represent the native status of PMN in
the blood stream. Nonetheless, Ral lost activity following chemoattractant stimulation in PMN
isolated using different methods, and Ral deactivation with time courses correlated with secondary granule release induced by either fMLF or IL-8. Thus, the results strongly suggest that Ral is
likely the specific GTPase that regulates PMN granule mobilization, and in particular, plays an
important role in controlling secondary granule release from PMN. Deactivation of Ral is likewise essential for PMN secondary granule release.
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changes of Ras family small GTPases including Ral, Ras and Rap in PMN. After time-course
stimulation with fMLF (1µM), PMN were lysed and active Ras, Ral and Rap were pulled down
using Raf-1 RBD, RalBP1 and RalGDS-RBD, respectively. In parallel, fMLF-induced PMN degranulation of secondary granules was assayed simultaneously by detecting lactoferrin in the
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the fMLF-containing lower chambers, or treated with damnacanthal were also assayed for active
Ral, Ras and Rap. Cell lysates before pull-down were used to detect total Ral, Ras and Rap, as
well as actin using antibodies against Ral, Ras, Rap and β actin.
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Figure 3-10. Ral deactivation correlates secondary granule release in PMN. Detecting activity
changes of Ral in PMN isolated using lympholyte-poly. After time-course stimulation with recombinant IL-8 (0.4µg/ml) (Sigma), PMN were lysed and active Ral was pulled downed using
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with Dunnett’s post tests) * indicates significant differences (p<0.05).
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Active Ral blocks secondary granule release in PMN.
To test that active Ral in resting PMN serves to prevent secondary granule release and that Ral
deactivation in response to chemoattractant stimulation is required for degranulation, I designed
experiments to over-express a constitutively active Ral, Ral23V, in PMN and tested its effect on
fMLF-induced degranulation. Since freshly isolated PMN are short-lived and not suitable for
protein expression by conventional gene transfection methods, I employed protein transduction
technology and directly delivered purified recombinant Ral into PMN by tagging the proteins
with an HIV Tat peptide (YGRKKRRQRRR) [54, 200, 216]. As demonstrated by previous studies, HIV Tat and other poly-arginine peptides have been widely used to transduce proteins of up
to 120kD into live cells [54, 200, 216] . Although PMN are highly sensitive and difficult to handle, using HIV Tat to study important intracellular molecules has been very successful [54, 217218]. In this study, three Tat-tagged Ral proteins were generated, including a wild-type Ral
(WT), a constitutively active mutant Ral (Ral23V), and a dominant negative mutant Ral
(Ral28N) [117, 167, 202]. As depicted in Figure 3-11, these proteins were first produced as recombinant GST fusions, followed by removal of GST and yielding Tat-tagged Ral. Figure 311B&C shows the stepwise production of Tat-tagged WT, Ral23V and Ral28N, and RalBP1
pull-down confirming that Ral23V was a constitutively active form.

To determine that Tat-tagged Ral proteins were capable of directly delivery into PMN, I chemically labeled the purified proteins with fluorescein (FITC), followed by incubation with PMN.
As shown in Figure 3-12A, fluorescence microscopy revealed that the three Tat-tagged Ral proteins (Tat-WT, Tat-Ral23V and Tat-Ral28N) were all rapidly delivered into PMN after only a
short incubation (10min) at a low temperature (4°C). Subsequent Western blot detected an over
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two-folds increase of Ral in PMN after incubating with each Tat-tagged Ral protein (Figure 312B). I also performed RalBP1 pull-down assays to test Ral activity after delivery of each Tattagged Ral protein into PMN. As shown in Figure 3-13, transduction of exogenous Ral23V into
PMN led to a sustained Ral activity in PMN even in the presence of fMLF stimulation, a condition that the endogenous Ral activity was completely diminished as that observed in the control,
non-peptide transduction PMN. Transduction of WT Ral or Ral28N, on the other hand, only
slightly (WT) or did not (Ral28N) increase Ral activity in PMN (Figure 3-13).

I next investigated whether Ral activity blocks fMLF-induced PMN degranulation. In these experiments, PMN were first loaded with Tat-tagged WT Ral, Ral23V or Ral28N, and then stimulated with fMLF. As shown in Figure 3-14A, no spontaneous PMN degranulation was detected
by just loading Tat-tagged Ral proteins (unstimulated). Prominent release of secondary granules
was induced by fMLF in PMN loaded with WT Ral or Ral28N, or without peptide delivery. On
the contrary, transduction of the constitutively active Ral, Ral23V, into PMN strikingly blocked
secondary granule release in the presence of fMLF. As shown in Figure 3-14, both lactoferrin
release (Figure 3-14A) and CD47 translocation to the cell surface plasma membrane (Figure 314B) were inhibited by Ral23V in PMN in spite of fMLF stimulation. However, Ral23V had no
effect on fMLF-induced tertiary granule release or the retention of primary granules (Figure 315A), further suggesting that Ral selectively regulates secondary granule mobilization.

Given that PMN degranulation of secondary granules is crucial for chemotaxis, I thus performed
PMN transmigration assays and examined the effect of Ral23V. As shown in Figure 3-15B, as
expected, transduction of Ral23V into PMN significantly reduced PMN transmigration towards
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fMLF, while WT Ral or Ral28N had no inhibition. In conclusion, these results demonstrated that
Ral activity blocks secondary granule release from PMN. Therefore chemoattractant-induced Ral
deactivation is essential for PMN degranulation, activation and chemotaxis.

In order to further investigate whether active Ral inhibits fMLF-induced PMN secondary granule
release regardless of what PMN isolation method is employed, transduction of Tat-tagged constitutively active Ral (Ral23V) into PMN isolated from “buffy coat” or using lympholyte-poly followed by assay of secondary granule release was carried out. In these experiments, PMN were
first loaded with Tat-tagged WT Ral, Ral23V or Ral28N, and then stimulated with fMLF. As
shown in Figure 3-16, 3-17, and 3-18, transduction of the constitutively active Ral, Ral23V, notably blocked both CD47 translocation to the cell surface plasma membrane (Figure 3-16 and
Figure 3-17) and lactoferrin release (Figure 3-18) regardless of fMLF stimulation. Overexpression of active Ral in PMN isolated from the “buffy coat”, using lympholyte-poly, or using
DEAE-DEXTRAN prevented secondary granule release, thus, further supporting the fact that
active Ral serves as a gate-keeper for degranulation of secondary granules from PMN.

Considering that the Ral gene is composed of RalA and RalB, I further explored the role of the
Ral gene in human PMN. As shown in Figure 3-19, studies of Ral expression in human leukocytes by RT-PCR detected both RalA and RalB in PMN. RalA and RalB are highly homologous
proteins and share most (if not all) of the functional domains identified to date, as shown in Figure 1-11 and Figure 1-12. The possible Ral downstream effector proteins relevant to our study
involved in receptor endocytosis, such as RalBP1/RLIP76, were found to bind to RalA and RalB
at sites with an identical amino acid sequence (aa 37-56). Although RalA and RalB have over-
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lapping functions, which have been reported by various studies, I further investigated the specific
role of RalB in PMN secondary granule release. In these experiments, I generated a Tat-tagged
constitutively active RalB (RalB23V) protein, followed by transduction of the protein into PMN,
and assayed its effect on secondary granule release. Transduction of RalB23V into PMN also
inhibited PMN mobilization of secondary granules shown by impaired lactoferrin release and
blockage of CD47 translocation to plasma membrane (Figure 3-20).
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Figure 3-11. Generation of Tat-tagged wild-type Ral (WT), constitutively active Ral (Ral23V),
and dominant negative Ral (28N) protein. A) A schematic depiction of Tat-tagged Ral production. The recombinant fusion proteins containing GST and Tat-Ral were produced, followed by
cleavage of GST with Factor Xa to yield Tat-Ral peptides. The figure also shows that two point
mutations, G23V and S28N, were created in Ral to produce constitutively active Ral (23V) and
dominant negative Ral (28N). B) A stepwise analysis of Tat-tagged Ral protein production by
SDS-PAGE and Coomassie blue staining. C) RalBP1 pull-down confirming that Tat-Ral23V was
a constitutively active GTPase. Purified Tat-tagged wild-type Ral, Ral23V and Ral28N (0.2µg
each) were incubated with GST-RalBP1 (1µg) and glutathione Sepharose in HBSS containing
5% non-fat dry milk, 2% BSA and 0.01% Tween 20 for 1h. After washing the precipitates,
Western blot was performed to detect active Ral pulled down by RalBP1.
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Figure 3-12. Transduction of Tat-tagged Ral proteins including wild-type Ral (WT), constitutively active Ral (Ral23V), and dominant negative Ral (28N) to PMN. A) Assaying Tat-tagged
Ral transduction into PMN. Tat-tagged wild-type Ral (WT), Ral23V and Ral28N (0.1µM of
each) were labeled with FITC followed by incubation with PMN for 10min at 4°C. B) Effective
transduction into PMN was then analyzed by Western blot.
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Figure 3-13. Tat-tagged constitutively active Ral sustained endogenous Ral activity in PMN.
After transduction of Tat-tagged Ral into PMN, PMN were stimulated with fMLF (1µM) for
20min at 37°C followed by cell lysis. RalBP1 pull-down were then performed to detect active
Ral. As shown, the result confirmed that transduction of Ral23V in PMN resulted in a sustained
Ral activity even with fMLF stimulation.
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Figure 3-14. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary
granule release in PMN. A) & B) Effects of Tat-tagged Ral proteins on fMLF-induced secondary granule release in PMN. PMN were incubated with purified Tat-tagged wild-type Ral (WT),
the constitutive active Ral (Ral23V) and dominant negative Ral (Ral28N) at concentrations of
10nM and 40nM, or control buffer (No peptide) (30min, 4°C) followed by stimulation with
fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was analyzed by measuring lactoferrin release in the cell-free supernatants (A) and cell surface labeling of CD47 by antiCD47 antibody PF3.1 (B) followed by flow cytometry (FACS). The data were subjected to a
one-way ANOVA (repeated measures, p<0.0001 with Dunnett’s post tests). * indicates significant differences in lactoferrin release from PMN with and without Tat-Ral23V transduction (p
<0.05).
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Figure 3-15. Specificity of Tat-tagged Ral proteins in PMN granule release. A) Tat-Ral23V has
no effect on the mobilization of primary and tertiary granules. B) Transduction of Tat-Ral23V
into PMN inhibited PMN chemotactic transmigration. Data (mean ± SD) represent three independent experiments with triplicates in each condition. The data were subjected to a one-way
ANOVA (repeated measures, p<0.0001 with Dunnett’s post tests). * indicates significant differences in cell number of migrated PMN with and without Tat-Ral23V transduction (p <0.05)
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Figure 3-16. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary
granule release in PMN isolated using lympholyte-poly. PMN were incubated with purified Tattagged wild-type Ral (WT), the constitutive active Ral (Ral23V) and dominant negative Ral
(Ral28N) at concentration of 40nM, or control buffer (No peptide) (30min, 4°C) followed by
stimulation with fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was analyzed by cell surface labeling of CD47 by anti-CD47 antibody PF3.1 (right panel) followed by
flow cytometry (FACS) (left panel).
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Figure 3-17. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary
granule release in PMN isolated directly from “buffy coat”. PMN were incubated with purified
Tat-tagged wild-type Ral (WT), the constitutive active Ral (Ral23V) and dominant negative Ral
(Ral28N) at concentration of 40nM, or control buffer (No peptide) (30min, 4°C) followed by
stimulation with fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was analyzed by cell surface labeling of CD47 by anti-CD47 antibody PF3.1 (right panel) followed by
flow cytometry (FACS) (left panel).
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Figure 3-18. Constitutively active Ral (Ral23V) inhibits chemoattractant-induced secondary
granule release in PMN isolated from “buffy coat” (A) and using lympholyte-poly (B). A) & B)
Effects of Tat-tagged Ral proteins on fMLF-induced secondary granule release in PMN. PMN
were incubated with purified Tat-tagged wild-type Ral (WT), the constitutive active Ral
(Ral23V) and dominant negative Ral (Ral28N) at concentration of 40nM, or control buffer (No
peptide) (30min, 4°C) followed by stimulation with fMLF (1µM) for 20min at 37°C. Degranulation of secondary granules was analyzed by measuring lactoferrin release in the cell-free supernatants. A) All the posts had significant difference compared with than no peptides (One-way
ANOVA, repeated measures, p<0.0002 with Dunnett’s post tests) B) All the posts had significant difference compared with no peptide treatment (One-way ANOVA, repeated measures,
p<0.0001 with Dunnett’s post tests) * indicates significant differences in lactoferrin release from
PMN with and without Tat-Ral23V transduction (p<0.05).
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Figure 3-19. Detection of RalA and RalB in human leukocytes. The RalA-specific and the
RalB-specific cDNA fragments, 777bps and 648bps, respectively, were RT-PCR amplified from
freshly isolated PMN and PMBC. The same DNA fragments were also PCR amplified from a
human leukocyte cDNA library (Marathon Ready cDNAs, Clontech). Given that RalA and RlaB
are highly homologous, the PCR primers were specially chosen based on the most dissimilar regions of their cDNAs. The primers for amplifying RalA were 5-ttccaggcgacaaggaccg agta and 5aagataagaaaggagtttggg. The primers for amplifying RalB were 5-atggctgccaacaagagtaag and 5agctggcttcatccgtcacctt. The amplified PCR fragments were DNA sequenced to confirm their
identities.
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Figure 3-20. Constitutively active RalB (Ral23V) inhibits chemoattractant-induced secondary
granule release. PMN were incubated with purified Tat-tagged wild-type RalB (WT), the constitutive active RalB (Ral23V) and dominant negative RalB (Ral28N) at concentration of 40nM or
10nM, or control buffer (No peptide) (30min, 4°C) followed by stimulation with fMLF (1µM)
for 20min at 37°C. Degranulation of secondary granules was analyzed by lactoferrin release (left
panel) and cell surface labeling of CD47 by anti-CD47 antibody PF3.1 (right panel). All the
posts had significant difference compared with no peptide treatment (One-way ANOVA, repeated measures, p<0.0001 with Dunnett’s post tests) * indicates significant differences in lactoferrin release from PMN with and without Tat-Ral23V transduction (p<0.05).
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Ral translocation between plasma membranes and secondary granules
Like Ras family GTPases, Ral contains a lipid modification site at the carboxyl terminus, suggesting that Ral may be associated with the cell membranes. To test this, I separated PMN membranes from the cytosol by ultracentrifugation in the absence of detergent. As shown in Figure
10A, Western Blot indicated that Ral is exclusively associated with the cell membranes in PMN.
To further localize Ral and define whether Ral is dynamically coupled with secondary granules, I
performed subcellular fractionation using sucrose density gradients. As shown in Figure 3-21,
the fractionations successfully separated PMN plasma membranes (alkaline phosphatase) from
secondary granules (lactoferrin) and primary granules (MPO). To my surprise, detection of Ral
in the fractions by western blots revealed that Ral is entirely associated with the plasma membrane in unstimulated PMN that is co-localized with another plasma membrane protein JAM-A.
Stimulation with fMLF, on the other hand, resulted in translocation of a considerable amount of
Ral to secondary granules (Figure 3-21B). In agreement with previous observation [68, 70], proteins initially stored in secondary granules, such as SIRPα, were redistributed to the plasma
membrane after fMLF stimulation following degranulation. As predicted, RalBP1 pull-down recovered active Ral from the plasma membrane fractions of unstimulated PMN, but not from secondary granule-rich fractions (Figure 3-22). I also performed immunofluorescence labeling and
observed that, as shown in Figure 3-23, Ral in unstimulated PMN was co-localized with the
plasma membrane marker wheat germ agglutinin (WGA) [219]. Stimulation with fMLF induced
a significant dissociation of Ral from WGA, suggesting Ral redistribution in PMN.

One major mechanism of plasma membrane internalization in PMN after chemoattractant stimulation is through clathrin-mediated cell surface receptor endocytosis [208, 220], and a previous
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study demonstrated that a Ral effector is complexed with a component of clathrin pits [121].
Therefore, I examined whether fMLF-induced Ral translocation from the plasma membrane to
intracellular granules followed this pathway.

Two inhibitors, dynasore [193] and a AP-2 binding Eps15 C-terminal peptide (Eps15-DIII)[194195], which specifically act on the clathrin-dependent endocytosis were examined. As shown in
Figure 3-24A, pre-treatment of PMN with dynasore (80 µM) and recombinant Eps15-DIII (40
nM), or their combination, appeared to have no inhibition on Ral translocation to secondary granules after fMLF stimulation. Dynasore inhibits dynamin, an essential GTPase regulating clathrin-coated pit fission, while Eps15-DIII inhibits clathrin-mediated endocytosis through sequestration of AP-2 thus interferes formation of the clathrin coat. To effectively use Eps15-DIII in the
study, this peptide was tagged with HIV-Tat, which significantly facilitated protein transduction
into PMN (Figure 3-24B). I also confirmed the function of the Eps15-DIII by protein pull-down
assays, which demonstrated that Eps15-DIII successfully co-precipitated AP-2 from PMN lysates (Figure 3-24C).

In addition to dynasore and a AP-2 binding Eps15 C-terminal peptide (Eps15-DIII), I also included several other traditional endocytosis inhibitors that act on the clathrin-dependent endocytosis including hypertonic sucrose (0.5M)[221], salt (0.76M NaCl)[222], phenylarsine oxide
(POA)[223], chlorpromazine (CPZ)[196], and cytosolic acidification (succinic acid, pH5.5)
[197-198]. As shown in Figure 3-25A, blocking clathrin-mediated endocytosis in PMN with
classical inhibitors resulted in a partial or complete inhibition of fMLF-induced secondary granule release. Remarkably, as shown in Figure 3-25B, these reagents also abolished Ral deactiva-
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tion after fMLF stimulation. In addition, contrary to the fact that dynasore and the Eps15 peptide
failed to exhibit inhibitory effects, CPZ and succinic acid remarkably blocked Ral translocation.
Subcellular fractionations demonstrated that, as shown in Figure 3-24A, blockage of clathrindependent endocytosis by CPZ [196] or cytosolic acidification (succinic acid, pH5.5) through
inhibition of the pinching off of clathrin-coated pits [197-198] eliminated Ral translocation from
plasma membranes to secondary granules in response to fMLF. These two inhibitors also effectively blocked fMLF-induced secondary granule release as indicated by a failure of translocation
of secondary granule proteins (e.g. SIRPα) to the plasma membrane (Figure 3-24A). As predicted, immunofluorescence labeling revealed a failure of Ral dissociation from the plasma
membrane marker WGA in the presence of those two endocytic inhibitors (Figure 3-23, lower
panel).

The results demonstrated that only classical inhibitors including CPZ and succinic acid were able
to block Ral translocation from plasma membrane to secondary granules upon fMLF stimulation.
Considering the nonspecificity of classical inhibitors for clathrin-mediated endocytosis, these
results suggest that clathrin-mediated endocytosis might not be involved in Ral intracellular
translocation and deactivation.

Considering that Ral deactivation and translation results in PMN secondary granule release, the
role of Ral in damnacanthal-mediated PMN secondary granule release was explored. Results,
however, were not conclusive (Figure 4-5, 4-6, 4-7).
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Localization of Ral in PMN. A) Ral is associated with membranes. PMN

(2.5×107) were dounce-lysed followed by ultracentrifugation to separate cytosol from cell membranes. SDS-PAGE and Western blot were performed to detect Ral in the total lysate before centrifugation (total PMN) and in the separated cytosol and membranes. B) Subcellular localization
of Ral in PMN. PMN (108/per condition), unstimulated and fMLF-stimulated, were lysed and
subjected to sucrose density gradient centrifugation to separate the plasma membrane and intracellular granules followed by fractionation. Western blots (lower panel) were performed to detect
Ral, SIRPα and JAM-A in the fractions using antibodies against Ral, anti-SIRPα.ex and antiJAM-A.ex. JAM-A is a transmembrane protein consistently expressed in the plasma membranes.
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Active Ral

Figure 3-22. In unstimulated PMN, Ral is active in plasma membrane and inactive in secondary
granules. PMN (108/per condition) were lysed and subjected to sucrose density gradient centrifugation to separate the plasma membrane and intracellular granules followed by fractionation.
Active Ral was pulled down using RalBP1 from plasma membrane, secondary granules, 1KS
(dounced lysate in the absence of detergent), and total cell lysate. SDS-PAGE and Western blot
were performed to detect active Ral using antibody against Ral.
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Figure 3-23. Localization of Ral in PMN. Immunofluorescence labeling of Ral in PMN. PMN,
unstimulated and fMLF-stimulated, were fixed and permeabilized with 0.02% Triton X-100.
After washing and blocking, cells were labeled with anti-Ral antibody (green) and plasma membrane marker wheat germ agglutinin (WGA) (red).
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Figure 3-24. Ral translocation from the plasma membrane to secondary granules may follow
fMLF-induced endocytic process. A) Effect of clathrin-dependent endocytic inhibitors on Ral
redistribution in PMN. In these experiments, PMN were pre-incubated with dynasore (80µM),
Tat-tagged Eps15 peptide (Eps15-DIII) (40nM), or a combination of the two reagents for 15min
(25°C) before fMLF stimulation (20min at 37°C). After cell lysis, subcellular fractionation was
performed followed by detection of Ral by Western blots. The effect of other endocytosis inhibitors, CPZ (50µM) and succinic acid (20mM, pH5.5), on Ral distribution was also tested. B) Protein transduction of Tat-tagged Eps15-DIII into PMN. Purified Tat-tagged Eps15-DIII was fluorescent labeled followed by incubating with PMN for 10min (4°C). The image shows that Eps15DIII was successfully delivered into the cells. C) Pull-down assay confirmed that Eps15-DIII directly binds to AP-2 complexes. PMN (1.5x107) were lysed in a buffer containing 1% Trition X100 and protease inhibitors followed by incubation with 10µg purified Tat-tagged Eps15-DIII in
the form of GST fusion protein or its non-binding control peptide Tat-tagged Eps15-Δ for 3h
(4°C). After pull-down with glutathione Sepharose, the precipitated protein complexes were
washed and analyzed by western blot using antibody against α-adaptin, an important component
of AP-2 complexes.
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Figure 3-25. Blockage of clathrin-dependent endocytosis inhibits fMLF-induced secondary granule release (A), Ral deactivation (B) and Ral translocation (C). In these experiments, PMN were
incubated with hypertonic solutions (0.5M sucrose and 0.76M NaCl), POA (20µM), CPZ
(50µM), succinic acid (20mM, pH5.5), or a mixture of later three reagents (combination) for
5min (25°C) before fMLF stimulation (20min at 37°C). Release of lactoferrin into the supernatants was measured (A). Ral activity was detected by RalBP1 pull down assays (B). All the posts
were significantly lower than HBSS and vehicle control (One-way ANOVA, repeated measures,
p<0.0001 with Dunnett’s post tests) * indicates significant differences (p<0.05). There was no
significant difference between HBSS and vehicle control (p>0.05).
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CHAPTER IV:
DISCUSSION
As a type of highly specialized and fast responsive cells, PMN store a large number of functionally important molecules in the intracellular granules and vesicles. Upon stimulation, PMN
promptly mobilize these granules/vesicles and rapidly release arrays of cell adhesion molecules,
receptors, and proteases to the cell surfaces to facilitate PMN adhesion, chemotaxis and microbial killing. At least four types of granules and vesicles varied in size/shape and content have been
identified in PMN [25, 96], but the mechanisms that control their mobilization and release during
PMN response to inflammatory stimulation remain largely undefined. Among these granules and
vesicles, secondary granules are defined as being mostly rich in leukocyte integrins and adhesive
receptor-like proteins. Degranulation of secondary granules thus serves as a major means to furnish the cell surface plasma membrane with the essential cell adhesion and migration molecules.
Here, we report our studies of PMN degranulation which reveal, for the first time, that the Ras
family member, Ral, is a critical regulator specifically in the degranulation of secondary granules.

As shown by my results, Ral exits as an active GTPase in freshly isolated PMN and its activity
plays a key role in keeping secondary granules in the cell. Inhibition of Ral in resting PMN by
damnacanthal, a Ras family GTPase inhibitor with unclear mechanism [206-207], causes “premature” liberation of secondary granules in the absence of chemoattractant stimulation. However, this dysregulated degranulation has no benefit to, but instead impeded PMN function. As I
observed, although damnacanthal increased cell surface integrins and adhesive molecules, these
upregulated molecules failed to mediate effective PMN interactions, adhesion and migration. In
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particular, my results (Figure 3-4) showed that, in contrast to fMLF-induced CD47 on the cell
surface that mediates binding interactions with its extracellular ligand, damnacanthal-induced
CD47 on PMN were incapable of binding interaction. Similarly, cell surface upregulated
CD11b/CD18 by damnacanthal did not appear to mediate strong extracellular interactions, which
count, in part, for the decrease of PMN adhesion and spreading in response to fMLF. Thus, these
results suggest that a critical mechanism, which is generally elicited by chemoattractant stimulation, is required to control secondary granule degranulation and, along this process, also converts
essential cell surface proteins to be functional and ready to mediate cell surface interactions.
These studies thus further signify the important role of Ral in PMN. By preventing irregular degranulation in the absence of stimuli, the Ral-mediated mechanism preserves PMN functional
capability for potent and effective response during inflammation.

In this study, I also obtained the important result that chemoattractant induces a rapid deactivation of Ral in PMN, which explains a dynamic regulation required for secondary granule release.
In contrast, experimentally over-expression of a constitutively active Ral, Ral23V [117, 167,
202], into PMN to sustain Ral activity even in the presence of fMLF resulted in prohibition of
secondary granule release, and hence hampered PMN chemotactic transmigration. While its role
in secondary granule mobilization is evident, Ral has no control of the mobilization of primary
and tertiary granules, and both damnacanthal and Ral23V only had effect on the degranulation of
secondary granules.

The mechanism by which Ral regulates secondary granule storage and release is unclear. By
subcellular fractionation, I found that Ral is associated with the plasma membrane under resting
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conditions, while chemoattractant stimulation triggers a translocation of Ral to secondary granules. Presumably, chemoattractant-induced cell surface endocytosis plays an important role in
Ral intracellular translocation, and thus PMN degranulation. Since PMN chemoattractant receptors are G protein-coupled, and clathrin-coated pits are generally employed to internalize these
receptors after ligand binding, one possible hypothesis would be that Ral is in complex with the
chemoattractant receptor and assembled into the clathrin pits after chemoattractant stimulation.
However, testing this hypothesis using two inhibitors, dynasore and an AP-2 binding Eps15 peptide, both specific blockers of clathrin-dependent endocytosis, failed to inhibit Ral translocation
to the pool of secondary granules. Interestingly, several other inhibitors that generally inhibit endocytosis, vesicle transportation and/or cytoskeleton structures blocked Ral intracellular translocation in the experiments.

In different cells, Ral has also been implicated in other types of vesicle transportation, including
both endocytosis and exocytosis [117-121]. However, the detailed mechanism regulating Ral activity is not clearly understood.

In platelets, it was found that Ral is inactive under resting conditions but becomes activated after
stimulation [163]. Contrary to our observation in this study, scientists in another study showed
that Ral is inactive in resting PMN [215], a variation that was likely caused by different methods
of cell preparation. In other studies, a guanine nucleotide dissociation stimulator, RalGDS, has
been suggested to be important in regulating Ral [164, 224], and such regulation involves Ras. In
particular, RalGDS was shown to directly bind to Ras, suggesting that Ral acts as a downstream
effector in the Ras network [167, 225]. However, evidence obtained from my studies fall short of
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supporting an important role of RalGDS in Ral-mediated degranulation in PMN. First, I found
that the expression of RalGDS in PMN is trivial compared to many other cell types (Figure 4-1),
and is also in no match for the abundance of Ral (Figure 4-1A). Second, subcellular fractionations detected no co-localization of RalGDS and Ral in PMN under either resting or fMLFstimulated conditions. Contrary to Ral, which is translocated between plasma membrane and
granules, RalGDS is consistently localized in the cytosolic fractions (Figure 4-1B). Studies of
other cells have shown that RalGDS directly binds to Ras, suggesting that Ral acts as a downstream effector in the Ras network [201, 225]. However, I found that, in PMN, Ral has a completely different activity profile from that of Ras (Figure 3-6), suggesting a dissociation of Ral
from the Ras pathway and a dispensable role for RalGDS in this regard.

While the mechanism of activation of Ral is vital, especially during PMN maturation, in order to
restrain produced granules in PMN, my results suggest the later mechanism that deactivates Ral
is also undoubtedly crucial for converting naive PMN into potent, functional inflammatory leukocytes. This mechanism, which is evidently important for PMN degranulation, remains unknown. Specific molecules that promote Ral deactivation, such as GTPase activating proteins
(GAPs), are hardly detected in any cell types including PMN.

Previous studies have indicated a role of intracellular calcium in secondary granule release, the
mechanism of how calcium functions is unclear. During chemoattractant (e.g. fMLF or IL-8)
stimulation, the intracellular calcium concentration in neutrophils is generally increased to the
peak ~10sec post-stimulation, followed by a quick decrease to the basal level (in the next ~1min)
regardless of the continuous presence of the chemoattractant (Figure 4-2A). However, in the
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same experimental setting, the robust release of secondary granules is observed approximately
starting at ~1min and continuously to a much later time point (>30min) (Figure 4-2B). Thus, the
time-course discrepancies of transient calcium increase in neutrophils versus the elongated release of secondary granule release after chemoattractant stimulation suggest that calcium likely
serves as an important secondary messenger or a modulator, which activates downstream signaling molecules directly involved in the control of secondary granule release. Since inhibition of
Ral by damnacanthal triggers neutrophil degranulation in the buffer without calcium (in HBSS ()) (Table 1 & Figure. 3-1), I thus do not consider that damnacanthal-mediated downstream events
(deactivation of Ral and secondary granule release) involve calcium or calcium signaling. However, my results did not exclude the possibility that calcium may regulate a step upstream of Ral
deactivation. Indeed, Ral structurally contains a calmodulin binding site. Detailed studies of Ral
activity at the very early phase of fMLF stimulation (within 1min) also sometimes showed a
slight increase (10-20%) of Ral activity at 10-30sec (Figure 4-3A), a time-course correlating with
the increase of intracellular calcium concentration. However, in vitro binding assays using the
purified recombinant Ral and RalBP1 (one of the effectors of Ral) failed to demonstrate a direct
involvement of calcium in Ral binding to this effector (Figure 4-3B).

Surprisingly, during my work, I found that Mg2+ inhibited Ral activity in PMN, as demonstrated
by a pull-down assay (Figure 4-4). Ral activity was strikingly increased in the presence of 2 mM
EDTA, while EDTA did not change Ral activity in resting platelets (Figure 4-4A and Figure 37B). Since EDTA is a chelator for both Ca2+ and Mg2+, both cations are likely to be involved in
regulating Ral activity. In order to dissect further which cation was the possible upstream inhibitor of Ral, I first stimulated PMN with fMLF in HBSS (-) buffer without Ca2+ and assayed Ral
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activity by pull-down. As shown in Figure 4-4B, stimulation of PMN in HBSS (-) failed to inhibit Ral activity compared with stimulation of cells in HBSS (+). In addition, stimulation of PMN
in the buffer supplemented with 5mM EGAT, a specific chelator for Ca2+, did not have any effect on Ral activity change. These results agree with other results (Figure 4-3B) and suggest that
Ca2+ is not a regulator of Ral activity. Mg2+, however, inhibited Ral activity, which is shown in
Figure 4-4C. Lysis of PMN in the presence of 30 mM Mg2+ abolished Ral activity. All of these
results illustrate that Mg2+ is the potential upstream inhibitor of Ral in PMN.

Treatment of PMN with damnacanthal in the absence of chemoattractant stimulation results in
secondary granule release. However, the detailed mechanisms underlying damnacanthalmediated secondary granule release from PMN are unclear.

It is obvious that the effect of damnacanthal on PMN is different from that of CB. As shown in
Figure 3-1, treatment of PMN with fMLF+CB triggered robust PMN degranulation of all the
granules including primary, secondary and tertiary granules. Treatment of PMN with damnacanthal, with or without fMLF, affected only the release of secondary granules. In experiments, I
observed that pre-treatment of PMN with low dose damnacanthal (< 10 µM) followed by fMLF
stimulation resulted in further degranulation in addition to the effect of damnacanthal alone (Figure 4-5). However, this manner of “synergenic” effect on secondary granule release was not observed with pre-treatment of PMN with higher doses of damnacanthal (>10 µM), which alone
triggered a near complete degranulation or complete degranulation without fMLF stimulation
(Figure 3-1). Pretreatment of PMN with damnacanthal had no effect on fMLF-induced tertiary
granule release (Figure 4-5). I further questioned whether receptor-mediated endocytosis in-
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volves in damnacanthal-mediated PMN secondary granule release. As shown in Figure 4-6 and
Figure 4-7, treatment of PMN with only the endocytosis inhibitors had no effect on Ral distribution. In addition, pretreatment with endocytosis inhibitors appeared to have no effect, or only
partial effect on damnacanthal-induced secondary granule release and Ral translocation from the
plasma membranes to the granules. These results, together with our other data (Figure 3-24),
suggest that Ral deactivation might not be downstream of endocytosis or along the process of
endocytic pathway.

Taking everything into consideration, our results demonstrate that it is important to elucidate Ral
activation and its importance in PMN; however, the mechanism that deactivates Ral is crucial for
PMN degranulation, thus converting to functional inflammatory leukocytes. Ral deactivation
correlates with clathrin-mediated endocytosis. Further studies of the signaling pathways and the
precise protein interactions involved in clathrin-dependent Ral translocation would provide clues
to resolve Ral conformational changes. In addition to Ral, other small GTPases, such as Ras family members Ras and Rap, and Rho family members Rho, Rac and Cdc42 are also expressed in
PMN [226-227] and some of these are found to be associated with granules [124, 131, 228].
Thus, detailed investigation of these small GTPases in PMN, and correlation of their activity
changes with PMN activation and degranulation will shed new light on the understanding of
PMN inflammatory functions. Given the critical role of PMN in innate immunity and inflammation, our findings illustrate a novel mechanism that modulates the PMN inflammatory response,
which may provide a potential therapeutic target for treating various inflammatory conditions.
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Figure 4-1. A) Expression of RalGDS in different cell types. Western blots were performed to
detect RalGDS in the cytosol fraction of PMN (lane 1, same as Fig.5A) and total lysates of various cell types using an anti-RalGDS antibody (Millipore). As shown, only slight amount of
RalGDS was detected in PMN cytosol, total PMN lysates or PMN-like, DMSO-induced HL-60
cell lysates. The same nitrocellulose membrane was re-blotted by anti-Ral antibody. The protein
loading of each lane was normalized by detecting actin in the lysates. B) RalGDS localization in
PMN. After subcellular fractionation, Western blots were performed to detect RalGDS and Ral
in the cytosolic and membrane fractions. As shown in the figure, RalGDS was exclusively localized in the cytosolic fractions in both unstimulated and fMLF-stimulated PMN and had no colocalization with Ral which was associated with the plasma membrane and/or secondary granules.
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Figure 4-2. A study of chemoattractant stimulation-induced increase of intracellular calcium,
secondary granule release and Ral activity changes in PMN. A) Chemoattractant stimulation
induces an increase of intracellular calcium in PMN. Freshly isolated PMN (1x106) were loaded
with the calcium indicator Indo-1 (Invitrogen) followed by washing. Labeled PMN in 1ml HBSS
were transferred into a cuvette (Starstedt) and placed into the spectrofluorimeter that had been
thermostated to 37°C. After equilibration, PMN were stimulated with 1µM fMLF (at 50sec position) and cytoplasmic [Ca2+] changes were immediately recorded with fluorescence emission at
505nm and double excitation wavelengths of 340 nm and 380nm using an intracellular cation
software (Hitachi). The concentrations of intracellular [Ca2+] were calculated using the Grynciewitz equation (R-Rmin) / (Rmax-R) * Kd (Kd is 2.54 x 10-7 M in this experiment). Rmax and
Rmin were measured by adding digitonin (10µM) and then EGTA (20mM) to Indo-1-loaded
PMN. Autofluorescence was corrected by stimulation of non-Indo-1-loaded PMN. The method
of detecting intracellular calcium in PMN was also described previously [192]. B) A parallel
experiment detecting secondary granule release. PMN (2x106) were resuspended in 0.1ml HBSS
and equilibrated to 37°C. Following stimulation with 1µM fMLF for different time periods, the
cell-free supernatants were collected after centrifugation and the released lactoferrin was assayed
by ELISA using an anti-lactoferrin antibody.
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Figure 4-3. A study of chemoattractant stimulation-induced increase of intracellular calcium,
secondary granule release and Ral activity changes in PMN. A) Ral activity changes in PMN
after fMLF stimulation. In this experiment, PMN (1x107) were stimulated with 1µM fMLF at
37°C in HBSS for different time periods. After cell lysis, active Ral in PMN was recovered by
RalBP1 pull-down followed by Western blot using an anti-Ral antibody. As can be seen in the
figure, Ral activity was slightly increased (10-30%) immediately after fMLF stimulation (at ~1030 second). B) Calcium concentrations have no effect on the direct binding of RalA to RalBP1.
In these experiments recombinant GST-RalBP1 and Tat-tagged wild-type and mutant RalA were
produced by expression in E.coli followed by protein purification. Pull-down assays were performed by incubation (30min, 4°C) of GST-RalBP1(1µg) with Tat-tagged Ral (0.2µg each) in
HBSS containing 5% non-fat dry milk, 2% BSA, 0.01% Tween 20 and different concentrations
of CaCl2. Glutathione-conjugated Sepharose (20µl) were also added. After washing, proteins
pulled down by the Sepharose were analyzed by Western blot using an anti-Ral antibody. As can
be seen in the figure, only the constitutively active Ral (Ral23V) was directly pulled down by
RalBP1. Increasing calcium concentrations had no effect on the direct binding of Ral to RalBP1.
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Figure 4-4. Mg2+ inhibits Ral activity in PMN. A) Ral activity in freshly isolated PMN was increased in the presence of EDTA. PMN were lysed in the presence or absence of 2mM EDTA,
and active Ral was pulled down using RalBP1. In addition, resting platelets were lysed in the
presence of 2mM EDTA, and active Ral was pulled down by RalBP1. B) Detecting activity
changes of Ral in PMN. PMN were stimulated with fMLF (1µM) in HBSS (-), HBSS (+), or
HBSS (+) supplemented with 5mM EGTA. After time-course stimulation, PMN were lysed, and
active Ral was pulled down. Cell lysates before pull-down were used to detect total Ral as well
as actin using antibodies against Ral and β actin. C) Detecting activity changes of Ral in PMN.
PMN were lysed in the presence of 5mM EDTA or 30nM Mg2+, and active Ral was detected by
pull down assay.
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Figure 4-5. Effects of damnacanthal alone or in a combination with fMLF on PMN granule release. In these experiments, aliquots of freshly isolated PMN (1x107) were treated with vehicle
(0.1% DMSO, 15min, 25°C), damnacanthal (3.6µM and 9µM, 15min, 25°C), fMLF (1µM,
15min, 37°C), or damnacanthal (3.6µM, 15min, 25°C) followed by fMLF (1µM, 15min, 37°C).
An aliquot of PMN resuspended in HBSS(-) and kept at 25°C (15min) was also used as a control
condition. After incubation, cell-free supernatants were collected after centrifugation and assayed
for granule release. Left: assay of PMN secondary granule release by detecting lactoferrin in the
supernatants. Right: Assay of PMN secondary granule release by zymogram detecting liberated
gelatinase in the supernatants.
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Figure 4-6. Subcellular fractionations studying the effects of damnacanthal and endocytosis inhibitors on Ral distribution in PMN. Damnacanthal triggers Ral redistribution from the plasma
membranes into secondary granules. Freshly isolated PMN (1x108/per condition) were treated
with vehicle (0.1%DMSO) or damnacanthal (9µM) for 15min (25°C) before lysis and subjected
to sucrose density gradients to separate subcellular organelles. After fractionation, the localizations of plasma membranes and intracellular granules in respective fractions were determined by
their specific marker proteins (upper panels). The lower panels show the Western blot results
detecting Ral, SIRPα and JAM-A (junction adhesion molecule A) in the fractions. In PMN,
SIRPα is mainly stored in secondary granules in the absence of stimulation, while JAM-A is
consistently associated with the plasma membrane (unpublished data). As can be seen, a portion
of Ral was redistributed from the plasma membranes into secondary granules after damnacanthal
treatment. Given that damnacanthal induces secondary granule release, it was predictable to observe that a portion of SIRPα was translocated to the plasma membranes. The indifferent JAM-A
localization demonstrated that plasma membrane integrity was not jeopardized by damnacanthal.
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Figure 4-7. Subcellular fractionations studying the effects of damnacanthal and endocytosis inhibitors on Ral distribution in PMN. Inhibitors acting on clathrin-mediated endocytosis had no
effect on damnacanthal-triggered Ral redistribution in PMN. In these experiments, PMN, pretreated with an individual endocytosis inhibitor (e.g. CPZ, 50µM) or a combination of several
inhibitors (50µM CPZ + 20µM POA + 20mM succinic acid (pH5.5)) (10min, 25°C), were either
subjected or not subjected to further treatment with damnacanthal (9µM) (15min, 25°C). After
treatment, the cells were lysed followed by to sucrose density gradient centrifugation to separate
subcellular organelles. After fractionation, Western blots were performed to detect Ral distribution in the fractions using an anti-Ral antibody. As shown in the figure, none of the endocytosis
inhibitors markedly blocked damnacanthal-triggered Ral redistribution from the plasma membranes to secondary granules.
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CHAPTER V:
APPENDICES (Data from other publications)
I.

PUBLICATION: ZEN K, CHEN CX, CHEN YT, WILTON R, LIU Y.RECEPTOR FOR

ADVANCED GLYCATION ENDPRODUCTS MEDIATES NEUTROPHIL MIGRATION
ACROSS INTESTINAL EPITHELIUM.J IMMUNOL. 2007 FEB 15; 178(4):2483-90.
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Figure 5-1. RAGE was amplified from human intestinal epithelial cells by RT-PCR. Results
showed that two fragments were amplified. Sequencing results showed that the longer fragment
was 1.2kb matching the full-length RAGE (GeneBank # AB036432) and the shorter fragment
was 0.9kb matching a N-terminal truncated RAGE form (GeneBank # AB061669).
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Figure 5-2. RAGE was detected from epithelial cell lines by western blot. RAGE was detected
from human colonic epithelial cells lines including T84 and HT29. RAGE was also detected
from epithelial cell A549.
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Figure 5-3. RAGE was detected in intestinal epithelial cells by immunofluorescence staining.
Confluent T84 intestinal epithelial monolayers were quickly permeabilized and fixed with methanol (10min, 4°C) followed by blocking with 5% normal goat serum. RAGE was detected using anti-RAGE antibody followed by labeling with FITC-conjugated goat anti-mouse IgG
(H+L). Imaging was analyzed by confocal microscope (Zeiss).
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Figure 5-4. Generation of GST-exRAGE fusion protein. RAGE was amplified from the plasmid
pcDNA3-RAGE-GST using the primers RAGE ECORI 91-F (ATATGAATTCGCTCAAAACATCACAGCCCGGATT) and RAGE-XhoI (ATATCTCGAGTGGTTCGATGATGCTGATGCT) and cloned into the vector (pGEX-5X1) through ECORI and XhoI, respectively. GST-exRAGE fusion protein (61KD) was produced in the same way described in 2.7.1.
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Figure 5-5. RAGE antibody titer test by ELISA. 96-well microtiter plate wells were coated with
RAGE-ex/GST fusion proteins (5μg/ml each) overnight at 4ºC.After blocking with 1% BSA
(30min, 25ºC), the wells were incubated with serum (1:200; 1:500; 1:1000; 1:2000; 1:5000;
1:100000) for 30min. After washing, fusion protein binding to the antibody (serum) was detected
by peroxidase conjugated goat anti-mouse Fc antibody.
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Figure 5-6. RAGE antibody titer test by western blot. The serum from the mouse RAGE-ex(RL)
and RAGE-ex(R) recognized the RAGE-Fc fusion protein, including the nonreducing form (A)
and reducing form. (B). Antibody also picked the band form the HT29, PMN and monocyte. After immunization for 5 times, the serum was used for WB at 1:1000 dilution.
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Figure 5-7. RAGE detection from human PMN. RAGE was detected from human PMN using
RAGE-ex serum. 3 samples out of 12 samples were RAGE positive.
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Figure 5-8. Generation of GST-JAML fusion protein. JAML-ex (AJ515553) was amplified from
the Leukocyte cDNA library with the primers JAML-151-BamH I (ATAT GGATCC TGAATGACTTGAATGTTTCC) and JAML-898-Xho I (ATAT CTCGAG CAACTGATTACCACCCAAGAC) and cloned into the vector (pGEX-5X1) through BamH I and Xho I, respectively.
JAML-CT was amplified from the leukocyte cDNA library with the primers JAML-979-BamH I
(ATATGGATCCTGGTGAAGAAGACCTGTGGAAAT) and JAML-1278-XhoI
(ATATCTCGAGAAGGGACTCTCCATTCTTCT) and cloned into the vector (pGEX-5X1)
through BamH I and Xho I, respectively.
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Figure 5-9. JAML antibody titer test by ELISA and western blot. 96-well microtiter plate wells
were coated with RAGE-ex/GST fusion proteins (5μg/ml each) overnight at 4ºC.After blocking
with 1% BSA (30min, 25ºC), the wells were incubated with serum (1:200; 1:500; 1:1000;
1:2000; 1:5000; 1:100000) for 30min. After washing, fusion protein binding to the antibody (serum) was detected by peroxidase conjugated goat anti-mouse Fc antibody. JAML was detected
from human PMN and monocytes using anti-JAML-ex serum and anti-JAML-CT serum at
1:1000 dilution.
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PMN

Lym

Mono

Figure 5-10. JAML was expressed on PMN and monocytes. Human whole leukocytes were surface labeled using anti-JAML-ex serum and anti-JAML-CT serum (control), respectively. RAGE
expression was detected from PMN (R1 group) and monocytes (R2 group), but no lymphocytes
(R3 group).
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III.

PUBLICATION: Liu Y, Tong Q, Zhou Y, Lee HW, Yang JJ, Bühring HJ, Chen YT, Ha

B, Chen CX, Yang Y, Zen K. Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47. J Mol Biol. 2007 Jan 19;365(3):680-93
Generation of SIRPα -IgV DNA constructs

Site-mutagenesis of the residues in Bit IgV loop to corresponding
counter amino acids in SIRPβ
Transient transfection to COS cells
Purification of SIPRα fusion protein
Assaying the binding capacity of SIRPα to its ligand, CD47

Figure 5-11. Ala57, Gln67, and Val57 were key amino acid residues mediating binding interaction of SIRPα to CD47.
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